<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006075</article-id><article-id pub-id-type="pmc">PMC11859690</article-id><article-id pub-id-type="doi">10.3390/ph18020262</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-18-00262</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Drug Treatment Direction Based on the Molecular Mechanism of Breast Cancer Brain Metastasis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yumin</given-names></name><xref rid="af1-pharmaceuticals-18-00262" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Shang</surname><given-names>Haotian</given-names></name><xref rid="af1-pharmaceuticals-18-00262" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Jiaxuan</given-names></name><xref rid="af2-pharmaceuticals-18-00262" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Yizhi</given-names></name><xref rid="af1-pharmaceuticals-18-00262" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jiahao</given-names></name><xref rid="af1-pharmaceuticals-18-00262" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Xiong</surname><given-names>Huihua</given-names></name><xref rid="af1-pharmaceuticals-18-00262" ref-type="aff">1</xref><xref rid="c1-pharmaceuticals-18-00262" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Chao</surname><given-names>Tengfei</given-names></name><xref rid="af1-pharmaceuticals-18-00262" ref-type="aff">1</xref><xref rid="c1-pharmaceuticals-18-00262" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Berzal-Herranz</surname><given-names>Alfredo</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Meegan</surname><given-names>Mary J.</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Rauter</surname><given-names>Am&#x000e9;lia Pilar</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-18-00262"><label>1</label>Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; <email>zhangmin200186@gmail.com</email> (Y.Z.); <email>m202276295@hust.edu.cn</email> (H.S.); <email>m202376699@hust.edu.cn</email> (Y.J.); <email>m202276284@hust.edu.cn</email> (J.L.)</aff><aff id="af2-pharmaceuticals-18-00262"><label>2</label>Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; <email>jiaxuanzhang@126.com</email></aff><author-notes><corresp id="c1-pharmaceuticals-18-00262"><label>*</label>Correspondence: <email>lizaabear@tjh.tjmu.edu.cn</email> (H.X.); <email>turnface@126.com</email> (T.C.)</corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>18</volume><issue>2</issue><elocation-id>262</elocation-id><history><date date-type="received"><day>17</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>10</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Today, breast cancer (BC) is the most frequently diagnosed malignancy and a leading cause of cancer-related deaths among women worldwide. Brain metastases (BMs) are a common complication among individuals with advanced breast cancer, significantly impacting both survival rates and the overall condition of life of patients. This review systematically analyzes the innovative approaches to drug treatment for breast cancer brain metastases (BCBMs), with particular emphasis placed on treatments targeting molecular mechanisms and signaling pathways and drug delivery strategies targeting the blood brain barrier (BBB). The article discusses various drugs that have demonstrated effectiveness against BCBM, featuring a mix of monoclonal antibodies, nimble small-molecule tyrosine kinase inhibitors (TKIs), and innovative antibody-drug conjugates (ADCs). This study of various drugs and techniques designed to boost the permeability of the BBB sheds light on how these innovations can improve the treatment of brain metastases. This review highlights the need to develop new therapies for BCBM and to optimize existing treatment strategies. With a deeper comprehension of the intricate molecular mechanisms and advances in drug delivery technology, it is expected that more effective personalized treatment options will become available in the future for patients with BCBM.</p></abstract><kwd-group><kwd>BCBM</kwd><kwd>Her2</kwd><kwd>WNT pathway</kwd><kwd>NOTCH pathway</kwd><kwd>CDK4/6inhibitors</kwd><kwd>BBB</kwd><kwd>LRP-1</kwd><kwd>VEGF</kwd><kwd>nanotechnology</kwd></kwd-group><funding-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>82001787</award-id></award-group><award-group><funding-source>WU JIEPING Medical Foundation Clinical Research Special Fund</funding-source><award-id>320.6750.2023-18-28</award-id></award-group><funding-statement>The authors gratefully acknowledge the financial support from National Natural Science Foundation of China (82001787) and WU JIEPING Medical Foundation Clinical Research Special Fund (320.6750.2023-18-28).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-18-00262"><title>1. Introduction</title><p>BC is currently the most prevalent neoplasm within females of all ages worldwide. Of patients with metastatic breast cancer (MBC), roughly 15&#x02013;30% develop brain metastases [<xref rid="B1-pharmaceuticals-18-00262" ref-type="bibr">1</xref>]. Over the last decade, median overall survival (OS) in patients with BCBMs has consistently been suboptimal, with only a small proportion surviving for 5 years or more [<xref rid="B2-pharmaceuticals-18-00262" ref-type="bibr">2</xref>]. BCBMs are swiftly emerging as a significant impediment to the survival of breast cancer patients. Previously, the treatment of survivors with BCBMs was based on localized treatments, like radiation therapy or surgery, but today, the utilization of drugs as systemic therapy is becoming increasingly important.</p><p>BMs develop for various reasons, like the molecular characteristics of cancer cells and signaling pathway alterations. Moreover, the BBB, as a special neurovascular unit, limits the penetration of antitumor drugs into the brain [<xref rid="B3-pharmaceuticals-18-00262" ref-type="bibr">3</xref>]. Many researchers have focused on these issues, particularly regarding anti-HER2 treatment and local treatment. In addition to focusing on anti-HER2 treatment, this review emphasizes other potential targets and studies clinical drugs, such as CDK4/6 inhibitors, Trop-2, PD-1/PD-L1, WNT and Notch pathway inhibitors. In addition, the role of BBB in brain metastasis in breast cancer is discussed, and methods for treating BCBM are explained through BBB delivery drugs, such as physical pathways to increase BBB permeability, the use of nanotechnology for drug delivery, and drug delivery routes targeting BBB endothelial cells. This review will discuss the therapeutic targeted drugs used for BCBM based on its molecular mechanisms and describe the role of the BBB in delivering drugs for treatment (<xref rid="pharmaceuticals-18-00262-f001" ref-type="fig">Figure 1</xref>).</p></sec><sec id="sec2-pharmaceuticals-18-00262"><title>2. Mechanisms of Brain Metastasis</title><p>From primary site development to the colonization in the brain, multiple steps are required (<xref rid="pharmaceuticals-18-00262-f001" ref-type="fig">Figure 1</xref>), including epithelial-mesenchymal transition (EMT), invasion, endocytosis, and extravasation [<xref rid="B4-pharmaceuticals-18-00262" ref-type="bibr">4</xref>]. Among these processes, EMT is a reversible procedure wherein mesenchymal characteristics are acquired by breast cancer cells (BCCs) [<xref rid="B5-pharmaceuticals-18-00262" ref-type="bibr">5</xref>]. Furthermore, mesenchymal cells are more metastatic and invasive than epithelial cells as they reduce the production of transmembrane E-calmodulin5 and increase the secretion of matrix metalloproteinase (MMP) and foster the breakdown of basement membrane proteins [<xref rid="B6-pharmaceuticals-18-00262" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceuticals-18-00262" ref-type="bibr">7</xref>]. These traits mean that BCCs are more likely to enter the bloodstream. This allows BCCs to access the blood circulation system more easily so they may develop into circulating tumor cells (CTCs). BCCs&#x02019; entry into the blood circulatory system is referred to as endocytosis, and the mechanism that can be identified is the involvement of macrophages. Intravascular macrophages attract tumor cells by producing epidermal growth factor (EGF) and release vascular endothelial growth factor (VEGF) to encourage EC proliferation, leading to the disruption of junctions between ECs, resulting in increased vascular permeability, which facilitates the entry of BCCs into the circulatory system from the paracellular pathway across the vascular endothelium [<xref rid="B8-pharmaceuticals-18-00262" ref-type="bibr">8</xref>]. In addition, the activation of Notch signaling stimulates the migration of BCCs. The activation of Notch signaling prompts Notch ligands on the EC surface to bind to Notch receptors on the BCC surface, thereby stimulating BCC migration [<xref rid="B9-pharmaceuticals-18-00262" ref-type="bibr">9</xref>]. CTC extravasates and colonizes the brain with blood circulation, and there are three types of BCBM: parenchymal, leptomeningeal, and choroid plexus metastases. Choroid plexus metastases are rare, leptomeningeal metastases account for 8% of cases, and parenchymal metastases are the most commonly occurring kind of brain metastasis, comprising 78% of multiple brain metastases and 14% of isolated brain metastases [<xref rid="B10-pharmaceuticals-18-00262" ref-type="bibr">10</xref>].</p><p>The extravasation of CTC into the brain parenchyma requires crossing the BBB, formed by ECs, pericytes and astrocytes that collectively regulate the homeostasis of the central nervous system (CNS), which collectively maintains normal brain function, with ECs significantly influencing the invasive capacitise of cancer cells [<xref rid="B11-pharmaceuticals-18-00262" ref-type="bibr">11</xref>]. It has been found that CTCs migrate within the vasculature by rolling, adhering, and, finally, completing transendothelial migration (TEM). Endothelial selectin (E-selectin) on the surface of ECs binds to the E-selectin ligand, CD44, and mucin 1 on cancer cells to guide the rolling process [<xref rid="B4-pharmaceuticals-18-00262" ref-type="bibr">4</xref>]. Intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) are overexpressed on the EC surface, with CTCs adhering to the ECs [<xref rid="B12-pharmaceuticals-18-00262" ref-type="bibr">12</xref>]. It was found that CTC mainly crosses the ECs through the paracellular pathway to complete TEM, and paracellular permeability is a major factor in TEM [<xref rid="B13-pharmaceuticals-18-00262" ref-type="bibr">13</xref>].</p><p>Paracellular permeability is predominantly regulated by the tight junctions (TJs) that exist between ECs. This regulation involves transmembrane proteins like occludins, claudins, and junctional adhesion molecules (JAMs), serving as essential components of TJs [<xref rid="B10-pharmaceuticals-18-00262" ref-type="bibr">10</xref>]. The adhesion of CTCs to the endothelium induces the destruction of these protein. Multiple mechanisms ultimately lead to TEM for CTC [<xref rid="B14-pharmaceuticals-18-00262" ref-type="bibr">14</xref>]. In addition, like endocytosis, VEGF is essential in exocytosis. The results of too high VEGF and angiopoietin-2 reduced the production of TJ proteins, disturbed intercellular junctions, and increased BBB permeability [<xref rid="B4-pharmaceuticals-18-00262" ref-type="bibr">4</xref>]. Moreover, astrocytes and pericytes preserve the functionality of the BBB. Astrocytes directly help ECs to grow and proliferate by secreting angiotensin 1 (ANG-1) and VEGF, thereby affecting the permeability of the BBB [<xref rid="B15-pharmaceuticals-18-00262" ref-type="bibr">15</xref>]. Pericytes are in close proximity to the EC and directly influence BBB permeability [<xref rid="B16-pharmaceuticals-18-00262" ref-type="bibr">16</xref>].</p><p>BCCs infiltrate and grow to form distant metastases, whereas glioblastoma (GBM) originates from glial cell tissue, grows infiltratively into the brain parenchyma, and almost never metastasizes [<xref rid="B17-pharmaceuticals-18-00262" ref-type="bibr">17</xref>]. However, both types of tumors must overcome the physical barriers provided by myoepithelial and astrocyte protrusions. In GBM, glioma cells are in direct contact with endothelial cells to destroy BBB. Additionally, in glioma, the existing vasculature is absorbed during initial tumorigenesis; however, subsequent tumor growth and hypoxia induce neoangiogenesis. This suggests the potential efficacy of VEGF inhibitors [<xref rid="B15-pharmaceuticals-18-00262" ref-type="bibr">15</xref>]. For intracerebral tumors, it is crucial to use drugs that can cross the BBB. Preclinical studies have shown that temozolomide can distribute across the BBB, blood-tumor barrier (BTB), and cerebrospinal fluid (CSF) in mice [<xref rid="B18-pharmaceuticals-18-00262" ref-type="bibr">18</xref>]. Currently, temozolomide is an important component of drug treatment for glioblastoma. However, its efficacy in breast cancer brain metastasis (BCBM) patients is limited [<xref rid="B19-pharmaceuticals-18-00262" ref-type="bibr">19</xref>], highlighting that different tumors exhibit varying BTB permeability.</p><p>Despite these differences, the overall treatment strategy remains the same: to deliver drugs across the BTB as effectively as possible to achieve therapeutic concentrations in the central nervous system (CNS).</p></sec><sec id="sec3-pharmaceuticals-18-00262"><title>3. Therapeutic Strategies Based on Molecular Mechanisms of BCBM</title><p>BC exhibits a higher propensity for the development of BM in advanced stages, and BM prognosis is usually poor. BM is particularly prevalent in the HER2-positive subtype of BC [<xref rid="B20-pharmaceuticals-18-00262" ref-type="bibr">20</xref>]. In recent years, many studies have identified various genes and abnormal signaling pathways mediating BCBM. These findings have advanced our comprehension of BM and provided ideas for the development of new treatment strategies [<xref rid="B21-pharmaceuticals-18-00262" ref-type="bibr">21</xref>].</p><sec id="sec3dot1-pharmaceuticals-18-00262"><title>3.1. HER-2 Gene Amplification</title><p>The propensity for pro-organ metastasis based on molecular subtypes showed increased brain parenchymal colonization and an increased probability of BM in the HER2-overexpressing subtype and triple-negative subtype [<xref rid="B22-pharmaceuticals-18-00262" ref-type="bibr">22</xref>]. Research indicates that BM overexpresses all members of the human EGF receptor (EGFR/HER) family, with HER2 being amplified and overexpressed in approximately 20% of these cases. Furthermore, inhibiting HER may be significant in the therapeutic management of patients with BCBM, even in case of low HER2 gene expression [<xref rid="B23-pharmaceuticals-18-00262" ref-type="bibr">23</xref>]. Therefore, clinical therapy based on HER-2-specific molecules is an important therapeutic direction for the management of BCBM (<xref rid="pharmaceuticals-18-00262-f002" ref-type="fig">Figure 2</xref>). A range of anti-HER2 therapeutics have been formulated for clinical application, encompassing monoclonal antibodies like trastuzumab and pertuzumab, small-molecule TKIs including lapatinib, neratinib, pyrotinib and tucatinib, and ADCs like T-DM1 and T-DXd. According to clinical guidelines (e.g., NCCN guidelines), trastuzumab and pertuzumab combined with chemotherapy are the first-line treatment options for the treatment of HER2-positive breast cancer patients. However, patients with advanced brain metastasis often have drug resistance to first-line medications, so other treatment options can be tried, such as ADC and TKI drugs. Except for pyrotinib, every drug mentioned have been approved by the FDA for the treatment of HER2-positive breast cancer. And they have shown good efficacy in patients with metastatic HER2-positive breast cancer (<xref rid="pharmaceuticals-18-00262-t001" ref-type="table">Table 1</xref>), providing a therapeutic direction for patients with BM, and some of these further retrospective studies, as well as new studies, have shown efficacy of these drugs in BM.</p><sec id="sec3dot1dot1-pharmaceuticals-18-00262"><title>3.1.1. Monoclonal Antibody</title><sec id="sec3dot1dot1dot1-pharmaceuticals-18-00262"><title>3.1.1.1. Trastuzumab</title><p>Research have found that breast cancer patients who received trastuzumab exhibited a obviously extended median duration to the progression of BM (15 months compared to 10 months) and a longer median survival time until death (14.9 months versus 4.0 months) than those who didn&#x02019;t take trastuzumab [<xref rid="B39-pharmaceuticals-18-00262" ref-type="bibr">39</xref>]. In addition, Rostami et al. provided evidence indicating that patients with BM resulting from HER2-positive BC had an extended mean survival following treatment with trastuzumab, reporting a longer mean survival of 17.5 months compared to 11 months for untreated patients.</p></sec><sec id="sec3dot1dot1dot2-pharmaceuticals-18-00262"><title>3.1.1.2. Pertuzumab</title><p>Furthermore, the integration of pertuzumab with trastuzumab and paclitaxel has shown enhanced efficacy compared to the conventional treatment regimen of trastuzumab and paclitaxel alone, as evidenced by an increase in median brain metastasis progression-free survival (PFS) from 11.9 months to 15 months. Additionally, the cohort receiving pertuzumab exhibited an extended median overall survival (OS) of 34.4 months, compared to 26.3 months in the control group [<xref rid="B40-pharmaceuticals-18-00262" ref-type="bibr">40</xref>].</p></sec></sec><sec id="sec3dot1dot2-pharmaceuticals-18-00262"><title>3.1.2. TKI</title><sec id="sec3dot1dot2dot1-pharmaceuticals-18-00262"><title>3.1.2.1. Lapatinib</title><p>In 2007, the U.S. FDA approved lapatinib combined with capecitabine for HER2-positive advanced or metastatic breast cancer patients. Lapatinib is a first-generation TKI that can reversibly inhibit HER1 and HER2. Its CNS objective response rate (ORR) of lapatinib-based monotherapy is only about 6% [<xref rid="B41-pharmaceuticals-18-00262" ref-type="bibr">41</xref>]. However, LANDSCAPE research has demonstrated that a combination of lapatinib and capecitabine had a CNS ORR of up to 65.9% and a median PFS of 5.5 months in patients with untreated BCBM. The RECIST 1.1 CNS ORR was 57% [<xref rid="B42-pharmaceuticals-18-00262" ref-type="bibr">42</xref>]. These data are the first to indicate the effectiveness of lapatinib in treating BCBM.</p></sec><sec id="sec3dot1dot2dot2-pharmaceuticals-18-00262"><title>3.1.2.2. Neratinib</title><p>As early as 2017, neratinib was approved by the US FDA for intensive adjuvant therapy after completion of adjuvant trastuzumab in adult patients with HER2-positive early-stage breast cancer. For patients with brain metastases, clinical trials have also confirmed that neratinib combined with capecitabine is effective for brain metastases in refractory HER2-positive breast cancer [<xref rid="B34-pharmaceuticals-18-00262" ref-type="bibr">34</xref>], and the specific benefit data are shown in <xref rid="pharmaceuticals-18-00262-t001" ref-type="table">Table 1</xref>, but about 30% of patients have adverse reactions to diarrhea, and efforts are needed to reduce diarrhea in order to better improve the quality of life of patients.</p></sec><sec id="sec3dot1dot2dot3-pharmaceuticals-18-00262"><title>3.1.2.3. Pyrotinib</title><p>Pyrotinib has not been approved by FDA, but clinical trials have also shown good efficacy. In addition to lapatinib, the phase II PERMEATE trial showed the superior therapeutic effect of pyrotinib in conjunction with capecitabine in patients diagnosed with HER2-positive BCBM: the trail included two different patient cohorts: patients exhibiting HER2-positive brain metastases who had not undergone radiotherapy (Cohort A) and those who had experienced disease progression following radiotherapy (Cohort B). The findings indicated that the intracranial ORR of cohorts A and B were 74.6% and 42.1%, and their mPFS time were 11.3 months and 5.6 months, which showed that the combination of pyrotinib and capecitabine had potential anticancer effect in patients who had not undergone radiotherapy [<xref rid="B35-pharmaceuticals-18-00262" ref-type="bibr">35</xref>]. Similarly, another non-randomized study focusing on HER2-positive BCBM patients demonstrated that CNS radiotherapy combined with pyrotinib and capecitabine showed a 1-year PFS rate of 74.9%, a median PFS of 18.0 months, and an ORR of 85% in the CNS [<xref rid="B43-pharmaceuticals-18-00262" ref-type="bibr">43</xref>].</p></sec><sec id="sec3dot1dot2dot4-pharmaceuticals-18-00262"><title>3.1.2.4. Tucatinib</title><p>The next-generation TKI drug tucatinib, a TKI specific for targeting HER2, has shown significant efficacy when used in conjunction with trastuzumab and capecitabine for treating patients with BM resulting from HER2+ breast cancer, as evidenced by the findings of the phase III HER2CLIMB clinical trial. The study focused on survivors with BM who had already undergone therapy with trastuzumab, pertuzumab and T-DM1 treatment, starting the patients who had taken tucatinib in conjunction with trastuzumab and capecitabine had an intracranial ORR of 47.3%, a mPFS of 9.9 months, and an mOS of 18.1 months, while the control group who received a placebo in conjunction with trastuzumab and capecitabine had an intracranial ORR of 20.0%, a mPFS of 4.2 months, and an mOS of 12.0 months [<xref rid="B44-pharmaceuticals-18-00262" ref-type="bibr">44</xref>]. This shows that tucatinib is useful for treating patients with BCBM.</p></sec></sec><sec id="sec3dot1dot3-pharmaceuticals-18-00262"><title>3.1.3. ADCs</title><sec id="sec3dot1dot3dot1-pharmaceuticals-18-00262"><title>3.1.3.1. T-DM1</title><p>As an increasingly important curative class, ADCs are effective drugs for the treatment of BCBM. Despite the relatively large size of the ADC molecule, it can penetrate the brain and release large quantities of cytotoxic drugs [<xref rid="B45-pharmaceuticals-18-00262" ref-type="bibr">45</xref>]. T-DM1, the earliest ADC sanctioned for BC treatment, consists of trastuzumab and the cytotoxic antimicrotubule compound DM1, interconnected by an irreversible thioether linker [<xref rid="B46-pharmaceuticals-18-00262" ref-type="bibr">46</xref>]. In 2013, the FDA approved it for the treatment of HER2-positive MBC patients who had received trastuzumab and first-line chemotherapy. Then in 2015, a retrospective and exploratory analysis of the EMILIA trial demonstrated an mPFS of 5.9 months (vs. 5.7 months) and mOS of 26.8 months (vs. 12.9 months) for T-DM1 compared to lapatinib in conjunction with capecitabine in BCBM patients previously treated with trastuzumab in combination with paclitaxel [<xref rid="B47-pharmaceuticals-18-00262" ref-type="bibr">47</xref>].</p></sec><sec id="sec3dot1dot3dot2-pharmaceuticals-18-00262"><title>3.1.3.2. T-DXd</title><p>T-DXd, a new ADC class, couples a monoclonal antibody targeting HER2 with a topoisomerase I inhibitor via a tetrapeptide shearable linker. In the DESTINY-Breast01 trial, 24 patients with brain metastases who received T-DXd had an average mPFS of 18.1 months, far exceeding the figure for patients receiving the standard treatment [<xref rid="B48-pharmaceuticals-18-00262" ref-type="bibr">48</xref>]. In addition, the DESTINY&#x02014;Breast03 study again validated the superior efficacy of T-DXd compared to T-DM1 in BCBM patients, with mPFSs of 15.0 and 3.0 months in 114 patients with BCBM in the two groups and ORRs of 67.4% and 20.5%, respectively in 2023 [<xref rid="B38-pharmaceuticals-18-00262" ref-type="bibr">38</xref>].</p></sec></sec></sec><sec id="sec3dot2-pharmaceuticals-18-00262"><title>3.2. Aberrant Signaling Pathway</title><p>Numerous aberrantly expressed genes and signaling pathways such as the dysregulation of Notch and WNT pathways, has been documented in individuals diagnosed with BCBM [<xref rid="B49-pharmaceuticals-18-00262" ref-type="bibr">49</xref>,<xref rid="B50-pharmaceuticals-18-00262" ref-type="bibr">50</xref>]. WNT and Notch pathways are primitive, conservative evolutionary pathways that determine cell destiny that are highly relevant to many facets of tumor biology, encompassing the sustenance of cancer stem cells (CSCs), angiogenesis, and immunity [<xref rid="B51-pharmaceuticals-18-00262" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceuticals-18-00262" ref-type="bibr">52</xref>]. Therefore, they can lead to tumor formation when they are abnormally activated.</p><sec id="sec3dot2dot1-pharmaceuticals-18-00262"><title>3.2.1. WNT Signaling Pathway</title><p>The WNT signaling pathway is overexpressed in individuals diagnosed with BC, particularly in those with BM, and the WNT-selective receptor ROR2 is also overexpressed. The importance of ROR2 in cancer initiation and progression has been demonstrated in vivo in a mouse model of basal-like TP53-deficient BC, and the silence of ROR2 inhibits cancer growth in the mouse brain, suggesting that WNT is related to cancer development and brain metastasis [<xref rid="B53-pharmaceuticals-18-00262" ref-type="bibr">53</xref>].</p><p>At the molecular level, the overexpression of the WNT-selective receptor ROR2 upregulates some non-classical WNT ligands, especially WNT11, and ligand-receptor binding regulated various functional proteins, increasing the invasiveness of breast cancer brain metastases [<xref rid="B54-pharmaceuticals-18-00262" ref-type="bibr">54</xref>]. In addition, endothelial WNT signal transduction affects the BBB by modulating the expression of various functional proteins [<xref rid="B55-pharmaceuticals-18-00262" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceuticals-18-00262" ref-type="bibr">56</xref>]. In patients with BCBM, the WNT signal controls the overexpression of the Mfsd2a protein [<xref rid="B57-pharmaceuticals-18-00262" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceuticals-18-00262" ref-type="bibr">58</xref>]. MFSD2A is a sodium-dependent lysophosphatidylcholine cotransporter that regulates the BBB&#x02019;s function by transporting lipids.</p><p>Studies have found that wogonin (WOG), an inhibitor of the WNT pathway [<xref rid="B59-pharmaceuticals-18-00262" ref-type="bibr">59</xref>], reversibly inhibits BBB WNT signaling and reduces Mfsd2a production. Applying nanoparticles for the delivery of WOG and orlistat enhances the intracranial accumulation of orlistat and inhibits tumor progression by releasing orlistat to interfere with tumor lipid metabolism. Rast studies have achieved good efficacy in mice with BCBM, improving the life quality in mice and significantly limiting intracranial tumor progression. The median survival time of mice increased to 24 days (that for nano-orlistat alone was 17 days), and it did not lead to cerebral edema, cognitive deficits, or widespread injury in normal mice [<xref rid="B60-pharmaceuticals-18-00262" ref-type="bibr">60</xref>].</p><p>Phase I clinical trials currently utilize the WNT inhibitor LGK974 to treat patients with metastatic colorectal cancer [<xref rid="B61-pharmaceuticals-18-00262" ref-type="bibr">61</xref>]. Porcupine (PORCN) is essential for WNT ligand secretion [<xref rid="B62-pharmaceuticals-18-00262" ref-type="bibr">62</xref>]. LGK974 is a specific inhibitor of porcupine that prevents cancer development by blocking WNT ligand secretion [<xref rid="B63-pharmaceuticals-18-00262" ref-type="bibr">63</xref>]. However, clinical trials investigating WNT inhibitor applications in patients with BCBM are still absent.</p></sec><sec id="sec3dot2dot2-pharmaceuticals-18-00262"><title>3.2.2. NOTCH Signaling Pathway</title><p>The Notch pathway is an extremely conservative evolutionary pathway for biologically measuring intercellular interactions and it is capable of interacting with transcriptional regulators in the nucleus to modulate the transcription of target genes that encode transcriptional regulatory proteins and related to some cellular biochemical activities such as differentiation, cell cycle progression [<xref rid="B64-pharmaceuticals-18-00262" ref-type="bibr">64</xref>].</p><p>Earlier studies have shown that BCCs with significant brain metastasis tendencies increase the activity of the Notch pathway through Notch1 and Jagged-2 (JAG2). In addition, the Jagged classical Notch ligand 1 (JAG1) has been proven to be overexpressed in metastatic breast cancer tissues, especially brain metastasis. JAG1 also induced Notch signaling in neighboring cells, and the activation of the JAG1-Notch pathway promoted the EMT of BCCs via the upregulation of transcriptional repressors, such as Slug. In addition, in a BBB model, the inhibition of the JAG1-Notch pathway by knocking down JAG1 significantly attenuated the ability of BCCs to penetrate the BBB, inhibiting their proliferation, migration, and invasion, thus suggesting that the JAG1-Notch pathway promotes the development of brain metastasis [<xref rid="B65-pharmaceuticals-18-00262" ref-type="bibr">65</xref>].</p><p>Notch pathway inhibitors developed based on this principle can be used as therapeutic methods for patients with BCBM. Researchers have demonstrated that Compound E, a &#x003b3;-secretase inhibitor with BBB permeability, as a Notch inhibitor, can significantly inhibit brain metastasis in an in vitro mouse model; dominant-negative MAML (dnMAML), a Notch-inhibitory peptide, is also a potent Notch inhibitor, and it significantly attenuates the growth of BCCs metastasizing in the brain [<xref rid="B66-pharmaceuticals-18-00262" ref-type="bibr">66</xref>]. However, the regulatory mechanism of the Notch signaling pathway is complex, and the best way to accurately regulate it to achieve precise therapeutic effects is still unknown, so its applications in clinical practice still needs to be extensive studied.</p></sec><sec id="sec3dot2dot3-pharmaceuticals-18-00262"><title>3.2.3. CDK4/6 Pathway</title><p>The cell cycle is the most significant method through which mammalian cells control proliferation. The G1 phase of the cell cycle is a critical phase of cell division that marks the beginning of the preparatory phases of growth and DNA replication following the completion of the last division, and this restriction point is key for regulating cell proliferation. This restriction point is regulated by the retinoblastoma pathway (CDK4/CDK6-cyclin D1-Rb-p16 / ink4a) [<xref rid="B67-pharmaceuticals-18-00262" ref-type="bibr">67</xref>]. The cell cycle protein D1 (cyclin D1) is overexpressed in most human BCCs, and cyclin D1 stimulates BCC proliferation by activating the cell cycle protein-dependent kinase 4/6 (CDK4/6) [<xref rid="B68-pharmaceuticals-18-00262" ref-type="bibr">68</xref>], whereas CDK4/6 inhibition induces cell cycle arrest in G1 cells, thereby inhibiting BCC proliferation [<xref rid="B69-pharmaceuticals-18-00262" ref-type="bibr">69</xref>]. CDK4/6 inhibitors developed based on this principle have made significant contributions to BC treatment. Currently, clinical studies are assessing the effects of CDK4/6 inhibitors in BCBM patients.</p><p>One CDK4/6 inhibitor, abemaciclib, was approved by the U.S. Food and Drug Administration (FDA) in 2017 for use in conjunction with endocrine therapy for breast cancer treatment. In general, for the systemic treatment of BM, drug delivery into the CNS is a major obstacle. However, preclinical studies have found that abemaciclib can traverse the BBB in mice and reach the CNS at an effective concentration, justifying its application in patients diagnosed with BCBM [<xref rid="B67-pharmaceuticals-18-00262" ref-type="bibr">67</xref>].</p><p>Past clinical trials have shown an intracranial ORR of 5.2%, an intracranial clinical benefit rate (CRB) of 25%, a median intracranial PFS of 4.9 months, and a median OS of 12.5 months in a cohort of 58 HR+/HER2-BCBM patients. Additionally, in this experiment, the average concentration of the drug in patient&#x02019;s cerebrospinal fluid (CSF) exceeded the half-maximal inhibitory concentrations (IC50) of CDK4 and CDK6 21 times and 4.3 times, respectively. Thus, these data proved that abeciclib and its active metabolites reached pharmacologically relevant concentrations in the brain and CSF of patients. These results further support the use of abemaciclib for treating patients [<xref rid="B70-pharmaceuticals-18-00262" ref-type="bibr">70</xref>].</p></sec><sec id="sec3dot2dot4-pharmaceuticals-18-00262"><title>3.2.4. Trophoblast Cell Surface Antigen-2 (Trop-2)</title><p>Trop-2 is a differentially expressed cell surface glycoprotein in epithelial tumors [<xref rid="B71-pharmaceuticals-18-00262" ref-type="bibr">71</xref>,<xref rid="B72-pharmaceuticals-18-00262" ref-type="bibr">72</xref>]. Trop-2 expression is elevated in breast cancer cells, stimulating cancer cell growth and enhancing tumor aggressiveness [<xref rid="B73-pharmaceuticals-18-00262" ref-type="bibr">73</xref>,<xref rid="B74-pharmaceuticals-18-00262" ref-type="bibr">74</xref>]. The Kaplan&#x02013;Meier survival curve showed that patients with breast cancer with high Trop-2 expression had significantly shorter survival times [<xref rid="B74-pharmaceuticals-18-00262" ref-type="bibr">74</xref>]. An analysis of the breast cancer genome revealed that Trop-2 was significantly overexpressed in triple-negative breast cancer (TNBC), suggesting that Trop-2 may be a potential target for TNBC [<xref rid="B75-pharmaceuticals-18-00262" ref-type="bibr">75</xref>]. However, normal brain tissue does not express Trop-2 [<xref rid="B76-pharmaceuticals-18-00262" ref-type="bibr">76</xref>], so Trop-2 may be a potential therapeutic target for BCBM.</p><p>An antibody-drug conjugate, sacituzumab govitecan (SG), has been developed for Trop-2 targets, consisting of an antibody targeting Trop-2 conjugated to SN-38 (topoisomerase I inhibitor) through a hydrolyzable linker. In a phase III clinical trial, for patients with metastatic TNBC, mPFS was 5.6 months versus 1.7 months and mOS was 12.1 versus 6.7 months for patients with SG versus chemotherapy [<xref rid="B77-pharmaceuticals-18-00262" ref-type="bibr">77</xref>], proving the excellent efficacy of SG.</p><p>Recently, a phase 0 window-of-opportunity trial of SG in BCBM patients showed that SG could achieve intratumoral concentrations of sufficient SN-38 to provide therapeutic benefit. In addition, a mouse model of the intracranial inoculation of triple-negative breast cancer cells verified that SG inhibited intracranial tumor growth, and the animal model showed that the control animal group had rapid tumor growth, with all animals dying at 45 days. However, the group of animals treated with SG had a reduced tumor burden, and all animals remained alive at 60 days. Moreover, the investigation encompassed 13 BCBM patients administered an intravenous dose of SG (10 mg/kg) the day prior to surgical intervention, followed by treatment in 21-day cycles, with doses received on days 1 and 8 of each cycle, commencing on postoperative day 1. An analysis of postoperative tissue samples revealed a median total concentration of SN-38 in BCBM of 249.8 ng/g, indicating that SG significantly penetrates intracranial tumors and exhibits promising efficacy within the CNS. The secondary endpoint of the study indicated an OS of 35.2 months, with PFS recorded at 8 months with an ORR of 38%. Additionally, an exploratory endpoint revealed that Trop-2 expression was present in 100% of the BCBM cases examined. The study provides strong support and evidence for treating BCBM with Trop-2 ADC and has important clinical significance [<xref rid="B78-pharmaceuticals-18-00262" ref-type="bibr">78</xref>].</p></sec><sec id="sec3dot2dot5-pharmaceuticals-18-00262"><title>3.2.5. Programmed Cell Death Protein-1 (PD-1)/Programmed Cell Death Ligand 1 (PD-L1)</title><p>PD-1 is a type I transmembrane protein composed of 288 amino acid residues, belonging to the CD28 family. It is widely expressed on various immune cells, including activated T cells, B cells, NK cells, and dendritic cells (DCs) [<xref rid="B79-pharmaceuticals-18-00262" ref-type="bibr">79</xref>]. Structurally, PD-1 comprises an extracellular immunoglobulin variable (IgV) domain, a hydrophobic transmembrane domain, and a cytoplasmic tail domain containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and immunoreceptor tyrosine-based switch motifs (ITSMs) [<xref rid="B80-pharmaceuticals-18-00262" ref-type="bibr">80</xref>].</p><p>PD-L1, the ligand for PD-1, consists of 290 amino acid residues and is primarily composed of a short cytoplasmic tail region, a transmembrane region, and extracellular IgV and IgC-like domains. PD-L1 is expressed on tumor cells and antigen-presenting cells (APCs), including dendritic cells and macrophages. Additionally, PD-L1 expression can be induced on vascular endothelial cells in response to interferon-gamma (IFN-&#x003b3;) stimulation [<xref rid="B81-pharmaceuticals-18-00262" ref-type="bibr">81</xref>]. Upon binding of PD-1 on T cells to PD-L1 on tumor cells or APCs, the ITIMs and ITSMs of PD-1 are phosphorylated, leading to the recruitment and activation of the protein tyrosine phosphatase SHP-2 (Src homology region 2 domain-containing phosphatase 2). This process inhibits T-cell activation, promotes T-cell apoptosis, reduces cytokine production, and induces antigenic tolerance, thereby facilitating tumor immune evasion [<xref rid="B82-pharmaceuticals-18-00262" ref-type="bibr">82</xref>].</p><p>BC has traditionally been considered a non-immunogenic tumor. However, recent studies have revealed that PD-L1 expression and tumor-infiltrating lymphocytes (TILs) are significantly higher in TNBC patients compared to other breast cancer subtypes, suggesting that TNBC exhibits strong immunogenicity and may be amenable to anti-PD-1/PD-L1 therapy [<xref rid="B83-pharmaceuticals-18-00262" ref-type="bibr">83</xref>,<xref rid="B84-pharmaceuticals-18-00262" ref-type="bibr">84</xref>]. Currently, pembrolizumab (a PD-1 inhibitor) and atezolizumab (a PD-L1 inhibitor) have been approved by the FDA for the treatment of PD-L1-positive, unresectable, locally advanced, or metastatic TNBC.</p><p>Clinical trials such as KEYNOTE-355, KEYNOTE-522, and KEYNOTE-173 have demonstrated promising efficacy and manageable adverse effects of pembrolizumab in the neoadjuvant treatment of early-stage TNBC at high risk of recurrence, as well as in TNBC patients resistant to multiline chemotherapy regimens [<xref rid="B85-pharmaceuticals-18-00262" ref-type="bibr">85</xref>,<xref rid="B86-pharmaceuticals-18-00262" ref-type="bibr">86</xref>,<xref rid="B87-pharmaceuticals-18-00262" ref-type="bibr">87</xref>]. However, these trials did not include patients with BM. Emerging preclinical and clinical studies support the use of anti-PD-1/PD-L1 therapy in patients with BM [<xref rid="B88-pharmaceuticals-18-00262" ref-type="bibr">88</xref>,<xref rid="B89-pharmaceuticals-18-00262" ref-type="bibr">89</xref>]. A preclinical study demonstrated that sequential in situ immunomodulation treatment combined with anti-PD-L1 therapy exhibited synergistic antitumor efficacy and improved survival in a mouse model of BCBM [<xref rid="B88-pharmaceuticals-18-00262" ref-type="bibr">88</xref>]. A phase II clinical trial involving 35 patients with BCBM (encompassing all four breast cancer subtypes) reported that 37% of patients achieved intracranial benefit from pembrolizumab treatment, with some experiencing mild adverse effects such as nausea, vomiting, and headache [<xref rid="B89-pharmaceuticals-18-00262" ref-type="bibr">89</xref>]. These findings suggest that anti-PD-1/PD-L1 therapy holds promise for patients with BM, although further trials are needed to validate these results.</p><p>The exploration of neoadjuvant therapy for early-stage BC in combination with immune checkpoint inhibitors remains limited but ongoing. For instance, an experimental approach combining the PD-L1 inhibitor atezolizumab with trastuzumab and pertuzumab was attempted in patients with HER2-positive BCBM. Unfortunately, no significant CNS benefits were observed in these patients [<xref rid="B90-pharmaceuticals-18-00262" ref-type="bibr">90</xref>]. Therefore, the potential benefits of PD-1/PD-L1 inhibitors for patients with BM require further investigation through additional studies.</p></sec><sec id="sec3dot2dot6-pharmaceuticals-18-00262"><title>3.2.6. In Summary</title><p>The treatment landscape for breast cancer brain metastases (BCBM) is evolving rapidly, with significant advancements in targeted therapies and a deeper understanding of molecular mechanisms. The following points summarize the current status and future directions for therapeutic strategies. Nowadays, anti-HER2 treatments have demonstrated substantial clinical benefits in patients with HER2-positive BCBM. Drugs such as trastuzumab, pertuzumab, lapatinib, neratinib, tucatinib, T-DM1, and T-DXd have shown significant efficacy in prolonging progression-free survival (PFS) and overall survival (OS) in clinical trials. The use of anti-HER2 therapies is well-established and recommended for patients with HER2-positive BCBM. Additionally, WNT and Notch signaling pathways play a crucial role in tumor biology and metastasis. However, their mechanisms are highly complex and diverse. Current research on WNT and Notch inhibitors is primarily at the preclinical stage. While these pathways show promise as therapeutic targets, further studies are needed to elucidate their roles and develop effective inhibitors for clinical use. In addition, the CDK4/6 inhibitor abemaciclib has shown promising results in HR+/HER2- BCBM patients. With its ability to cross the blood-brain barrier (BBB) and achieve effective concentrations in the brain, abemaciclib represents a new direction for the treatment of BCBM. Ongoing clinical trials are further exploring its potential in this patient population. Sacituzumab govitecan (SG), trop-2-targeted ADC, has demonstrated significant efficacy in preclinical models and clinical trials with small sample sizes. The promising results in both mice and patients suggest that SG could be a valuable treatment option for BCBM. Larger-scale clinical trials are warranted to confirm its efficacy and safety in a broader patient population. Anti-PD-1/PD-L1 therapies have achieved remarkable success in non-brain metastatic triple-negative breast cancer (TNBC) patients. However, data on their efficacy in patients with brain metastases are limited. Preclinical studies and early clinical trials have shown some potential benefits, but more research is needed to determine their role in the treatment of BCBM.</p><p>In conclusion, while significant progress has been made in the treatment of BCBM, there are still many challenges to overcome. Future research should focus on developing more effective targeted therapies.</p></sec></sec></sec><sec id="sec4-pharmaceuticals-18-00262"><title>4. Therapeutic Strategies Based on BBB Drug Delivery Pathways</title><p>The BBB regulates the homeostasis of CNS by establishing a meticulously controlled neurovascular unit (NVU) that preserves proper brain function, and it has an intact endothelium that can act as a defense barrier against tumor-cell extravasation; however, these properties also hinder drug delivery to the brain. During the invasion and infiltration of BCCs into the brain, the integrity of the BBB is disrupted and permeability is increased, but the TJ undergoes rapid remodeling during TEM and does not significantly damage the BBB [<xref rid="B91-pharmaceuticals-18-00262" ref-type="bibr">91</xref>]. In addition, the BBB has characteristics such as active efflux molecules [<xref rid="B15-pharmaceuticals-18-00262" ref-type="bibr">15</xref>]. Therefore, achieving drug delivery across the BBB is a significant issue when treating brain metastases. We need to discuss emerging strategies for enhancing medication transport across the BBB for the improved treatment of patients with BCBM.</p><sec id="sec4dot1-pharmaceuticals-18-00262"><title>4.1. Molecular Pathway</title><sec id="sec4dot1dot1-pharmaceuticals-18-00262"><title>4.1.1. LRP-1</title><p>Receptor-mediated transcytosis (RMT) is now used for the noninvasive delivery of drugs across the BBB. Proteins expressed by ECs on the BBB can be used for receptor-mediated BBB penetration of the cytosol, e.g., the transferrin receptor, insulin receptor, insulin-like growth factor 1 receptor, and LDL receptor [<xref rid="B92-pharmaceuticals-18-00262" ref-type="bibr">92</xref>]. In this case, binding the targeted ligand (e.g., a monoclonal antibody) to its receptor triggers endocytosis, followed by intracellular vesicular translocation and eventual release into the brain, and using this translocation mechanism, the drug can be molecularly ligated to this ligand to achieve translocation across the BBB via receptor-mediated endocytosis, e.g., by using endogenous expression of the BBB receptor, the low-density lipoprotein receptor-related protein-1 (LRP-1) [<xref rid="B93-pharmaceuticals-18-00262" ref-type="bibr">93</xref>], a recent RNA sequencing study found that LRP-1 mRNA was expressed at higher levels than the insulin receptor and TfR mRNA in isolated human cerebral vessels [<xref rid="B94-pharmaceuticals-18-00262" ref-type="bibr">94</xref>].</p><p>ANG1005 is a peptide&#x02013;chemotherapy coupled drug targeting LRP1, consisting of three paclitaxel molecules covalently attached to Angiopep-2 (a peptide engineered to exploit the LRP1 transport mechanism), which increases the spread of drugs to brain metastases through RMT (<xref rid="pharmaceuticals-18-00262-f001" ref-type="fig">Figure 1</xref>). Phase II trials have found that ANG-1005 shows activity against breast cancer and brain tumors. This phase II clinical trial enrolled 72 female BCBM patients, of whom 57% (41) were HER2-negative and 19 (26%) were TNBC patients. The findings showed that ANG 1005 demonstrated significant CNS efficacy, achieving an average intracranial ORR of 15% and an intracranial CBR of 68% for every patient. The median intracranial PFS and OS were recorded at 2.8 months and 7.8 months, respectively [<xref rid="B95-pharmaceuticals-18-00262" ref-type="bibr">95</xref>]. Currently, a phase III trial on ANG1005 is underway [<xref rid="B96-pharmaceuticals-18-00262" ref-type="bibr">96</xref>].</p></sec><sec id="sec4dot1dot2-pharmaceuticals-18-00262"><title>4.1.2. Overcoming the Efflux Pumps</title><p>BCBM cancer cells express greater amounts of breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp) than cancer cells derived from the primary tumor [<xref rid="B97-pharmaceuticals-18-00262" ref-type="bibr">97</xref>]. P-gp and BCRP are efflux pump transport proteins located at the BBB and restrict the uptake of substrate drugs into the brain, which can exclude the drug from the cytoplasm [<xref rid="B98-pharmaceuticals-18-00262" ref-type="bibr">98</xref>]. They do this by actively pumping out the drug so that drug concentrations in the brain reduce and drug levels fall well below the threshold necessary for therapeutic efficacy, leading to drug resistance. The current study suggests that P-gp excludes drugs from the cell via a twist&#x02013;squeeze mechanism. P-gp is embedded in the phospholipid bilayers of biological membranes and has two homologous transmembrane structural domains (TMDs) that bind substrates and two intracytoplasmic nucleotide-binding structural domains (NBDs) that bind ATP. The tilt&#x02013;shift of the two TMDs gives P-gp two conformations: the inward-facing type provides binding sites for intracellular drugs, while the outward-facing type promotes the efflux of bound drugs. When binding only ATP, P-gp can more stably maintain the inward conformation, and after binding the substrate again, the whole protein twists and moves, and the inward type is converted to the outward type, which directly squeezes the substrate to the outside of the cell [<xref rid="B99-pharmaceuticals-18-00262" ref-type="bibr">99</xref>]. Currently, many drugs exist that transport substrates for transfer proteins, such as the tyrosine kinase inhibitors (TKIs) lapatinib, erlotinib [<xref rid="B100-pharmaceuticals-18-00262" ref-type="bibr">100</xref>], and temozolomide, in which transporter proteins reduce the brain penetration of temozolomide and thus its anti-tumor efficacy [<xref rid="B98-pharmaceuticals-18-00262" ref-type="bibr">98</xref>]. Additionally, P-gp can transport paclitaxel, which contributes to the development of resistance to this drug [<xref rid="B101-pharmaceuticals-18-00262" ref-type="bibr">101</xref>].</p><p>Therefore, to combat intracerebral drug decreases mediated by efflux transporters, reduce drug resistance, and achieve intracranial effective concentration, preclinical investigations have concentrated on using transporter inhibitors to develop drugs. For example, one study has found that encequidar (HM30181A), a P-gp inhibitor, can enhance the uptake of paclitaxel and the anti-tumor effect of paclitaxel in an orthotopic brain tumor model [<xref rid="B102-pharmaceuticals-18-00262" ref-type="bibr">102</xref>]. A clinical trial (NCT02594371) demonstrated that patients with MBC receiving oral paclitaxel in combination with encequidar exhibited superior PFS and OS compared to those treated with intravenous paclitaxel. Specifically, the oral paclitaxel and encequidar cohort achieved a PFS of 8.4 months, while the intravenous paclitaxel group had a PFS of 7.4 months. Furthermore, the OS for the oral paclitaxel and encequidar group was recorded at 22.7 months, in contrast to 16.5 months for the intravenous paclitaxel group [<xref rid="B103-pharmaceuticals-18-00262" ref-type="bibr">103</xref>].</p><p>Utidelone (UTD-1) inhibits multidrug resistance through multiple pathways, including the inhibition of P&#x02043;gp-mediated mutations in the paclitaxel-binding region and the overexpression of transporter proteins [<xref rid="B104-pharmaceuticals-18-00262" ref-type="bibr">104</xref>]. Currently, the FDA has approved UTD-1 for use in patients with BCBM. At the 2024 American Society of Clinical Oncology (ASCO) meeting, an experiment (NCT05357417) investigating the combination of UTD-1 and bevacizumab for treating brain metastases from TNBC achieved a CNS ORR of 55% among participants. Additionally, the study reported a median PFS of 8.4 months, confirming that UTD-1 had good anti-tumor activity against brain metastases [<xref rid="B105-pharmaceuticals-18-00262" ref-type="bibr">105</xref>]. Another trial indicated that patients with MBC who exhibited resistance to anthracycline and paclitaxel experienced improved PFS, OS, and ORR when treated with UTD-1 plus capecitabine compared to those receiving capecitabine monotherapy. Specifically, the OS was 19.8 months for the combination therapy group, in contrast to 16 months for the group receiving capecitabine alone. The assessment of the PFS and ORR showed that the combination group had a median PFS of 8.6 months and an ORR of 49.8%, while the monotherapy group had a median PFS of 4.1 months and an ORR of 26.7%, which demonstrated the superiority of UTD-1 used in combination with capecitabine treatment over capecitabine monotherapy [<xref rid="B106-pharmaceuticals-18-00262" ref-type="bibr">106</xref>].</p></sec><sec id="sec4dot1dot3-pharmaceuticals-18-00262"><title>4.1.3. VEGF</title><p>The expression of VEGF was elevated in BCCs isolated from brain metastases in a preclinical experiment [<xref rid="B107-pharmaceuticals-18-00262" ref-type="bibr">107</xref>]. VEGF induces neovascularization by binding to VEGFR2 and activating the STAT3 and PI3K pathways, thereby enhancing vascular permeability, and downregulates vascular endothelial integrity to enhance brain metastasis in tumor cells [<xref rid="B108-pharmaceuticals-18-00262" ref-type="bibr">108</xref>].</p><p>Bevacizumab was the first targeted anti-angiogenic agent developed, and an E2100 study in patients with advanced MBC demonstrated that patients in the paclitaxel&#x02013;bevacizumab group had nearly 1-fold longer PFS than patients in the paclitaxel-alone group (mPFS 11.8 months vs. 5.9 months) [<xref rid="B109-pharmaceuticals-18-00262" ref-type="bibr">109</xref>]. The AVADO study demonstrated that PFS was much longer in patients with MBC who received bevacizumab in conjunction with docetaxel compared to those in the control group [<xref rid="B110-pharmaceuticals-18-00262" ref-type="bibr">110</xref>]. Similarly, another study (RIBBON-1) focusing on patients with MBC showed that patients receiving bevacizumab in conjunction with either capecitabine or a regimen of paclitaxel/anthracycline experienced a statistically obvious improvement in PFS compared to those administered chemotherapy alone. Specifically, the median PFSs were reported as 8.6 months versus 5.7 months and 9.2 months versus 8.0 months, respectively [<xref rid="B111-pharmaceuticals-18-00262" ref-type="bibr">111</xref>]. Nevertheless, as the study progressed, an analysis of the efficacy and safety data derived from these three clinical studies revealed that bevacizumab was only effective at prolonging PFS among patients; it did not demonstrate an improvement in OS. Additionally, the proportion of serious adverse reactions such as intracerebral hemorrhage increased [<xref rid="B109-pharmaceuticals-18-00262" ref-type="bibr">109</xref>,<xref rid="B110-pharmaceuticals-18-00262" ref-type="bibr">110</xref>,<xref rid="B111-pharmaceuticals-18-00262" ref-type="bibr">111</xref>]. Consequently, the authorization of bevacizumab use in conjunction with chemotherapy as a first-line therapy for advanced BC was rescinded.</p><p>Nonetheless, bevacizumab, an antibody targeting VEGF, as a humanized IgG1 monoclonal antibody that binds to VEGF with high affinity, is of clinical value in patients with BCBM. Bevacizumab showed favorable efficacy in a phase II trial in conjunction with carboplatin for treating patients with BCBM. The CNS ORR was 63%, median PFS was 5.62 months, and median OS was 14.10 months, with efficacy results exceeding historical data for platinum agents alone [<xref rid="B112-pharmaceuticals-18-00262" ref-type="bibr">112</xref>]. Another clinical trial with 112 patients examined whether adding bevacizumab, etoposide, and cisplatin (BEEP) prior to whole-brain radiotherapy (WBRT) improved brain-specific PFS. It was found that median brain-specific PFS was 8.1 and 6.5 months in the WBRT and BEEP group and the WBRT-alone group, respectively. However, there was no notable difference observed in brain-specific ORR at the two-month mark (BEEP and WBRT vs. WBRT, 41.9% vs. 52.6%). Meanwhile, the rate of brain-specific PFS was 48.7 versus 26.3 percent at 8 months. These findings suggest that BEEP induction chemotherapy prior to WBRT may inhibit brain metastasis progression compared to WBRT alone [<xref rid="B113-pharmaceuticals-18-00262" ref-type="bibr">113</xref>]. These data reveal the value of bevacizumab, an antibody targeting VEGF, in treating BCBM.</p><p>Targeting the VEGF-VEGFR system, PTK787, an orally effective selective VEGFR inhibitor, obviously limited angiogenesis and brain metastasis growth and increased apoptosis in tumor cells in preclinical models (<xref rid="pharmaceuticals-18-00262-f001" ref-type="fig">Figure 1</xref>).</p><p>Nevertheless, there was no notable enhancement in survival rates among the treated mice, possibly associated with cancer cells being able to express other cytokines, such as IL-8 [<xref rid="B114-pharmaceuticals-18-00262" ref-type="bibr">114</xref>]. IL-8 acts as a mediator of angiogenesis and induces endothelial cell proliferation, which induces angiogenesis even when VEGF receptor signaling is impaired, thereby promoting the progression of brain metastases [<xref rid="B107-pharmaceuticals-18-00262" ref-type="bibr">107</xref>]. After the infiltration of cancer cells into the brain, brain metastatic cells secreted VEGF and IL-8 in significantly higher contents than parental cells [<xref rid="B22-pharmaceuticals-18-00262" ref-type="bibr">22</xref>]. In contrast, AM9928, a potent covalent monoacylglycerol lipase (MAGL) inhibitor, was found to inhibit the secretion of IL-8 and VEGF in TNBC cells, thereby reducing TNBC colonization in the brain [<xref rid="B115-pharmaceuticals-18-00262" ref-type="bibr">115</xref>]. These outcomes imply that AM9928 can be used as a new drug for patients with TNBC brain metastases.</p></sec></sec><sec id="sec4dot2-pharmaceuticals-18-00262"><title>4.2. Physicochemical Pathway</title><p>Currently, multiple modalities of electromagnetic radiation and ultrasound are utilized to physically disrupt the BBB. For example, laser-induced interstitial thermotherapy (LITT) employs an implanted laser to achieve localized opening of the BBB, promoting the entry of antineoplastic agents into the rat brain [<xref rid="B116-pharmaceuticals-18-00262" ref-type="bibr">116</xref>]. Another approach is Focused Ultrasound (FUS), found in preclinical studies to allow easier drug passage through the BBB. FUS is associated with a microbubble system, where ultrasound penetrates deeper into soft tissues. The mechanical interactions between ultrasound, microbubbles, and the vascular system lead to the intermittent depolymerization of TJ proteins on the ECs of the BBB [<xref rid="B117-pharmaceuticals-18-00262" ref-type="bibr">117</xref>]. This process provides a transient opportunity to administer therapeutic medicines. The FUS-mediated remodeling of the BBB has been applied for the management of brain cancers located in various regions of the CNS. This technique enhances the permeability of a variety of antineoplastic agents such as temozolomide and paclitaxel, aiding their translocation across the BBB [<xref rid="B118-pharmaceuticals-18-00262" ref-type="bibr">118</xref>]. Preclinical experiments are now available to demonstrate that FUS and microbubbles in combination with weekly trastuzumab therapy enhance BBB permeability, improving efficacy in mice inoculated with HER2-positive mammary tumors in the brain, notably decreasing the average intracerebral tumor volume, as well as a substantially enhancing the survival duration of the mice [<xref rid="B119-pharmaceuticals-18-00262" ref-type="bibr">119</xref>]. Moreover, chemical irritation may induce endothelial contraction, leading to the instantaneous destruction of the BBB reversibly, as exemplified by a study on hypertonic mannitol solution [<xref rid="B117-pharmaceuticals-18-00262" ref-type="bibr">117</xref>].</p></sec><sec id="sec4dot3-pharmaceuticals-18-00262"><title>4.3. Application of Nanoparticles</title><p>Delivering generic drugs to brain tissue remains a challenge due to the BBB. For patients with BCBM, drug delivery system (DDS) must overcome this obstacle. Nanoparticles, as a class of ultrafine materials, exhibit unique physicochemical properties due to their extremely small sizes: as carriers of therapeutic drugs, they are more easily solubilized and encapsulated [<xref rid="B119-pharmaceuticals-18-00262" ref-type="bibr">119</xref>]. Therefore, nanoparticle-based DDS could achieve the efficient penetration of the BBB [<xref rid="B120-pharmaceuticals-18-00262" ref-type="bibr">120</xref>]. This means that patients with BCBM have a promising future in nanotherapeutics.</p><p>Many nanoparticles are being investigated for treating BCBM, including carbon-based, lipid-based, polymer-based, and metal-based nanostructures [<xref rid="B121-pharmaceuticals-18-00262" ref-type="bibr">121</xref>]. Compared with free medications, nanostructures can also selectively deliver medications to cancerous sites, stimulate more apoptosis in breast tumors, and significantly reduce the systemic toxicity of drugs. Research has demonstrated that nanostructures can facilitate the delivery of a diverse array of drugs; for example, metal nanoparticles and carbon nanoparticles can transport cisplatin to reduce its toxicity and enhance therapeutic efficacy [<xref rid="B122-pharmaceuticals-18-00262" ref-type="bibr">122</xref>]. Liposomal nanocarriers can be used to deliver doxorubicin; albumin nanoparticles in polymeric nanoparticles that can be used to deliver paclitaxel [<xref rid="B121-pharmaceuticals-18-00262" ref-type="bibr">121</xref>]. In addition, lipid nanoparticles can carry docetaxel. An animal study found that BCCs can rapidly absorb the docetaxel-loaded lipid nanoparticles. Moreover, docetaxel has higher brain bioavailability in this form, significantly inhibiting the development of BM and prolonging survival in a mouse model [<xref rid="B123-pharmaceuticals-18-00262" ref-type="bibr">123</xref>]. A preclinical animal study demonstrated that mice with BM receiving liposomal irinotecan achieved a superior survival rate compared to free irinotecan alone [<xref rid="B124-pharmaceuticals-18-00262" ref-type="bibr">124</xref>]. In addition to preclinical trials, a phase I clinical trial investigated the effects of liposomal irinotecan. This research found that in seven of these BCBM patients, tumor shrinkage ranged from 7% to 55%, the ORR in BCBM patients was 30%, and 50% of the patients achieved a significant clinical benefit [<xref rid="B125-pharmaceuticals-18-00262" ref-type="bibr">125</xref>].</p><p>In addition to delivering drugs, nanotechnology can be used for immunotherapy. The tumor microenvironment is a dynamic system that includes tumor cells, the extracellular matrix, and mesenchymal tissues. It is a key factor affecting tumor metastasis. Moreover, in the brain tumor microenvironment of BCBM patient, tumor-associated macrophage (TAM) represents the predominant cell type within the metastatic microenvironment [<xref rid="B126-pharmaceuticals-18-00262" ref-type="bibr">126</xref>]. TAM has both pro-inflammatory M1-like and anti-inflammatory M2-like phenotypes [<xref rid="B127-pharmaceuticals-18-00262" ref-type="bibr">127</xref>]. However, the majority of TAM belong to M2-like phenotypes, which can facilitate angiogenesis and reshape the extracellular matrix, thereby promoting tumor progression [<xref rid="B128-pharmaceuticals-18-00262" ref-type="bibr">128</xref>]. Therefore, when treating patients with BCBM, if TAM can be reprogrammed from the M2 to the M1 phenotype, it will enhance the tumor immune response.</p><p>Many experiments have studied the nanostructure of immunotherapy for BCBM. In detail, some studies have used nanoparticle-encapsulated drugs to target receptors on the TAM surface to inhibit TAM or to polarize M2-like TAM to M1-like TAM [<xref rid="B129-pharmaceuticals-18-00262" ref-type="bibr">129</xref>]. For example, dextran-coated magnetic nanoparticles (Ferumoxytol) can significantly inhibit breast cancer progression and metastasis in mice by generating reactive oxidative species (ROS) via the Fenton reaction that mediates the repolarization of TAM to the anti-tumor M1-like form [<xref rid="B130-pharmaceuticals-18-00262" ref-type="bibr">130</xref>]. In addition, copper sulfide nanoparticles (CuS NPs) increase intracellular ROS levels and facilitate the polarization of TAM to a M1-like phenotype in mice [<xref rid="B131-pharmaceuticals-18-00262" ref-type="bibr">131</xref>]. A study showed that binding SIRP&#x003b1; and CD47 on macrophages prevented macrophages from engulfing tumor cells [<xref rid="B132-pharmaceuticals-18-00262" ref-type="bibr">132</xref>]. The membrane-encapsulated magnetic nanostructure can obstruct the interaction between SIRP &#x003b1; and CD47, thereby maintaining the activity of macrophages to engulf breast cancer cells. Meanwhile, the magnetic core facilitates the repolarization of M2 macrophages to M1 macrophages. These combined effects contribute to the enhancement of immune responses and subsequently improve survival rates and prognostic outcomes for patients with breast cancer [<xref rid="B133-pharmaceuticals-18-00262" ref-type="bibr">133</xref>].</p><p>In addition, nano can induce photothermal therapy (PTT) to promote tumor cell death; gold nanoparticles of different sizes and dimensions can use different wavelengths of light to perceptually heat tumors by altering their photothermal and photoacoustic behaviors, killing breast cancer cells by heating them without overheating normal cells [<xref rid="B134-pharmaceuticals-18-00262" ref-type="bibr">134</xref>].</p></sec><sec id="sec4dot4-pharmaceuticals-18-00262"><title>4.4. Direct Infiltration</title><p>Temozolomide (TMZ), classified as a second-generation oral alkylating agent, can pass through the BBB readily. It mainly attacks the DNA of tumor cells, causing DNA alkylation damage and then forming DNA cross-links, leading to the death of cancer cells. TMZ is rapidly absorbed after oral administration and then crosses the BBB into the CSF, reaching an effective drug concentration [<xref rid="B135-pharmaceuticals-18-00262" ref-type="bibr">135</xref>].</p><p>However, a phase II trial [<xref rid="B136-pharmaceuticals-18-00262" ref-type="bibr">136</xref>] demonstrated that TMZ, administered orally to treat patients with brain metastases, resulted in transient stabilization in only three patients (durations of 2.7 to 5.6 months), with disease progression recorded in the remaining 15 patients. For five patients with brain metastases, temozolomide did not show any significant improvement in brain lesions. Another phase II clinical trial investigating WBRT combined with temozolomide in patients with BCBM showed an ORR of 36% versus 30% in the WBRT group versus WBRT and TMZ group at 6 weeks, a median PFS of 7.4 months versus 6.9 months, and a median OS of 11.1 months versus 9.4 months [<xref rid="B19-pharmaceuticals-18-00262" ref-type="bibr">19</xref>]. These experiments demonstrate that TMZ has limited potential for treating BCBM.</p></sec></sec><sec sec-type="discussion" id="sec5-pharmaceuticals-18-00262"><title>5. Discussion</title><p>This article details therapeutic strategies for BCBM, specifically drug therapy based on molecular mechanisms and delivery pathways across the BBB.</p><p>The molecular mechanisms underlying brain metastasis are intricate and encompass aberrant expression of numerous genes and signaling pathways. For instance, the HER2 gene is amplified, and the use of anti-HER2 drugs has been associated with enhanced patient survival in clinical settings. However, trastuzumab and pertuzumab are common with side effects such as cardiac dysfunction, rash, and fever. A trial of safety and tolerability in patients with HER2-positive breast cancer showed a higher incidence of diarrhoea and a higher incidence of neutropenia in the pertuzumab group than in the placebo group [<xref rid="B137-pharmaceuticals-18-00262" ref-type="bibr">137</xref>]. TKI drugs (such as lapatinib, pyrotinib, tucatinib) may also cause diarrhea, abnormal liver function, rash, etc. The combination of a TKI with trastuzumab is more likely to cause diarrhea than trastuzumab alone [<xref rid="B138-pharmaceuticals-18-00262" ref-type="bibr">138</xref>]. CDK4/6 inhibitors (such as abeciclib) may also cause neutropenia, leukopenia, anemia, etc. Long-term use may also cause adverse reactions such as fatigue, nausea, and vomiting [<xref rid="B139-pharmaceuticals-18-00262" ref-type="bibr">139</xref>].</p><p>ADC drug T-DXd may cause nausea, vomiting, fatigue, hair loss, etc. However, overall T-DM1 and T-DXd were manageable and safe for longer treatment durations [<xref rid="B38-pharmaceuticals-18-00262" ref-type="bibr">38</xref>]. Common treatment-related adverse events with sacituzumab govitecan (SG) include neutropenia, leukopenia, and anemia. But it is well tolerated in patients with metastatic triple-negative breast cancer who have received significant prior therapy [<xref rid="B140-pharmaceuticals-18-00262" ref-type="bibr">140</xref>]. In addition, PD-1/PD-L1 inhibitors may cause immune-related adverse events, such as immune pneumonia, immune hepatitis, and immune thyroid dysfunction [<xref rid="B141-pharmaceuticals-18-00262" ref-type="bibr">141</xref>].</p><p>Due to the complex mechanism of the signaling pathways and the involvement of multiple factors such as hypoxia in their activation, the precise role of activated Notch signaling in the brain-specific metastasis of tumor cells remains unclear [<xref rid="B49-pharmaceuticals-18-00262" ref-type="bibr">49</xref>]. Preclinical trials related to this have shown the potential to inhibit tumor growth, but its role still lacks clinical trial data to confirm. In addition, brain metastases from breast cancer may acquire driver mutations after metastasis to the brain and carry mutations not detected in samples from the primary site [<xref rid="B142-pharmaceuticals-18-00262" ref-type="bibr">142</xref>,<xref rid="B143-pharmaceuticals-18-00262" ref-type="bibr">143</xref>]. However, due to the small sample size, it is difficult to extract general evolutionary patterns between primary and metastatic foci, and biopsies of brain metastases in particular are more difficult. Currently, CSF interacting directly or indirectly with brain tumors may be a new direction for &#x0201c;liquid biopsies&#x0201d; based on brain tumor genetics [<xref rid="B144-pharmaceuticals-18-00262" ref-type="bibr">144</xref>].</p><p>The BBB restricts the entry of drugs into the CNS, such as trastuzumab and pertuzumab, due to their large molecular weight, making it difficult for them to cross the BBB. As a result, the concentration of these drugs in the CNS is significantly lower than in other parts of the body. Even if a drug successfully penetrates the BBB, tumor cells may develop resistance through multiple mechanisms, such as P-gp and LRP-1-mediated drug efflux. Therefore, our research is directed towards the development of enhanced drug delivery strategies that take into account the characteristics of this barrier. Examples include the utilization of RMT and the deployment of transporter protein inhibitors to augment the intracerebral concentration of the drug, thereby enhancing its therapeutic efficacy. Additionally, the article delineates various techniques for physically disrupting the BBB, as well as the utilization of nanocarriers (e.g., liposomes and gold nanoparticles) for the targeted delivery of drugs, ensuring efficient delivery to the tumor site while minimizing systemic toxicity. Despite diligent attempts to utilize a variety of nanocarrier, the anti-tumor efficacy of these carriers and their cumulative effect in the targeted tissues are still limited. To solve these challenges, various surface modifications (e.g., folic acid, histidine, transferrin, etc.) and stimulations (e.g., P and, enzymes, photothermal, etc.) have been applied to nanocarriers, but it is still a problem to accurately identify clinically applicable technologies from the wide variety of preclinical trials [<xref rid="B133-pharmaceuticals-18-00262" ref-type="bibr">133</xref>].</p><p>In addition, topical therapy is indispensable as an important complement to drug therapy. However, surgery is usually mainly applied to a single lesion and has limited effect on multiple brain metastases. WBRT may lead to irreversible cognitive impairment, with an increased risk of cognitive loss and a significant reduction in patients&#x02019; quality of life with prolonged treatment. Although SRS has relatively few side effects, it is only suitable for brain metastases with 1~3 metastases and lesions &#x02264; 3~4 cm in diameter, and it is still difficult to apply it multiple times [<xref rid="B145-pharmaceuticals-18-00262" ref-type="bibr">145</xref>].</p></sec><sec id="sec6-pharmaceuticals-18-00262"><title>6. Future Direction</title><p>With the deepening of research on the molecular mechanisms of brain metastasis, more targeted therapies targeting key signaling pathways and genes are being developed. There is still considerable scope for the development of targeted drugs based on HER2, WNT, Notch and other signaling pathways. In addition, three phosphoinositide 3-kinase (PI3K) inhibitors (alpelisib, buparlisib, and dactolisib) in combination with anti-estrogen agents are presently undergoing assessment for their efficacy in the treatment of hormone-positive BCBM. There are also various chemotherapy drugs and targeted drugs in combination with good results. For example, LANDSCAPE study showed that the combination of lapatinib and capecitabine in the first-line treatment of HER2+ BCBM demonstrated a CNS ORR of 65.9% in patients [<xref rid="B42-pharmaceuticals-18-00262" ref-type="bibr">42</xref>]. In addition, P-gp inhibitors can be used in combination with antineoplastic drugs to improve the activity of intracranial antineoplastic drugs and slow down the emergence of drug resistance. Paclitaxel and encequidar has shown promising effect in patients with MBC [<xref rid="B103-pharmaceuticals-18-00262" ref-type="bibr">103</xref>]. And the transporter inhibitor UTD-1 combined with capecitabine and bevacizumab showed anti-tumor activity and controllable toxicity in patients with brain metastases [<xref rid="B105-pharmaceuticals-18-00262" ref-type="bibr">105</xref>,<xref rid="B106-pharmaceuticals-18-00262" ref-type="bibr">106</xref>]. Therefore, the combination of UTD-1 and targeted drugs may be another new idea to overcome drug resistance and enhance drug efficacy, and it is worth conducting randomized controlled trials.</p><p>Improving drug delivery systems: Technologies that break through the BBB will be key to the therapy of brain metastases. Using new drug delivery systems like nanotechnology, combined with physical interventions (such as ultrasound and laser), can significantly enhance the penetration and intracranial efficacy of drugs.</p><p>The in-depth study of the molecular typing of breast cancer and the mechanism of brain metastasis will facilitate the development of personalized treatment options. The future treatment of patients will be tailored according to their molecular characteristics, with the most appropriate targeted drugs and treatments selected. Although the molecular mechanism of BCBM is currently understood to some extent, further clinical trials are required to verify the efficacy and safety of new drugs and treatment strategies. In the future, the combination of further clinical trials and real-world data will facilitate the determination of the optimal treatment and strategy. In general, the treatment is developing in a more precise and personalized direction, and with the advancement of drug delivery technology and the in-depth understanding of molecular mechanisms, the survival rate of breast cancer brain metastases patients is expected to be further improved in the future.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, Y.Z. and H.S.; writing&#x02014;original draft preparation, Y.Z., H.S. and Y.J.; writing&#x02014;review and editing, Y.Z., J.Z. and J.L.; supervision, T.C. and H.X. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no competing interests.</p></notes><glossary><title>Abbreviations</title><array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">ADC</td><td align="left" valign="middle" rowspan="1" colspan="1">antibody-drug conjugate </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BBB</td><td align="left" valign="middle" rowspan="1" colspan="1">blood-brain barrier </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BC</td><td align="left" valign="middle" rowspan="1" colspan="1">breast cancer </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BCBM</td><td align="left" valign="middle" rowspan="1" colspan="1">breast cancer brain metastases </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BCC</td><td align="left" valign="middle" rowspan="1" colspan="1">breast cancer cell</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BCRP</td><td align="left" valign="middle" rowspan="1" colspan="1">breast cancer resistance protein </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BM</td><td align="left" valign="middle" rowspan="1" colspan="1">brain metastases </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CDK4/6</td><td align="left" valign="middle" rowspan="1" colspan="1">cycle protein-dependent kinase 4/6 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CNS</td><td align="left" valign="middle" rowspan="1" colspan="1">central nervous system </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CRB</td><td align="left" valign="middle" rowspan="1" colspan="1">clinical benefit rate </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CSC</td><td align="left" valign="middle" rowspan="1" colspan="1">cancer stem cell</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CSF</td><td align="left" valign="middle" rowspan="1" colspan="1">cerebrospinal fluid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CTC</td><td align="left" valign="middle" rowspan="1" colspan="1">circulating tumor cell</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">cyclin D1</td><td align="left" valign="middle" rowspan="1" colspan="1">cell cycle protein D1 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DDS</td><td align="left" valign="middle" rowspan="1" colspan="1">drug delivery system</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EC</td><td align="left" valign="middle" rowspan="1" colspan="1">endothelial cell</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EGF</td><td align="left" valign="middle" rowspan="1" colspan="1">epidermal growth factor </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EMT</td><td align="left" valign="middle" rowspan="1" colspan="1">epithelial mesenchymal transition</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FUS</td><td align="left" valign="middle" rowspan="1" colspan="1">Focused Ultrasound </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ICAM-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Intercellular adhesion molecule-1 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">JAMs</td><td align="left" valign="middle" rowspan="1" colspan="1">junctional adhesion molecules </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LITT</td><td align="left" valign="middle" rowspan="1" colspan="1">laser-induced interstitial thermotherapy </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LRP-1</td><td align="left" valign="middle" rowspan="1" colspan="1">low-density lipoprotein receptor-related protein-1 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MBC</td><td align="left" valign="middle" rowspan="1" colspan="1">metastatic breast cancer </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MMP</td><td align="left" valign="middle" rowspan="1" colspan="1">matrix metalloproteinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NBD</td><td align="left" valign="middle" rowspan="1" colspan="1">nucleotide-binding structural domain</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NVU</td><td align="left" valign="middle" rowspan="1" colspan="1">neurovascular unit </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ORR</td><td align="left" valign="middle" rowspan="1" colspan="1">objective response rate </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OS</td><td align="left" valign="middle" rowspan="1" colspan="1">overall survival </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PFS</td><td align="left" valign="middle" rowspan="1" colspan="1">progression-free survival </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">P-gp</td><td align="left" valign="middle" rowspan="1" colspan="1">P-glycoprotein </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PTT</td><td align="left" valign="middle" rowspan="1" colspan="1">photothermal therapy </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RMT</td><td align="left" valign="middle" rowspan="1" colspan="1">receptor-mediated transcytosis </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ROS</td><td align="left" valign="middle" rowspan="1" colspan="1">reactive oxidative species </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SG</td><td align="left" valign="middle" rowspan="1" colspan="1">sacituzumab govitecan </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TEM</td><td align="left" valign="middle" rowspan="1" colspan="1">transendothelial migration </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TJs</td><td align="left" valign="middle" rowspan="1" colspan="1">tight junctions </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TKI</td><td align="left" valign="middle" rowspan="1" colspan="1">tyrosine kinase inhibitor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TMZ</td><td align="left" valign="middle" rowspan="1" colspan="1">Temozolomide </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNBC</td><td align="left" valign="middle" rowspan="1" colspan="1">triple negative breast cancer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">UTD-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Utidelone </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VCAM-1</td><td align="left" valign="middle" rowspan="1" colspan="1">vascular cell adhesion molecule-1 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VEGF</td><td align="left" valign="middle" rowspan="1" colspan="1">vascular endothelial growth factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">WBRT</td><td align="left" valign="middle" rowspan="1" colspan="1">whole-brain radiotherapy </td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-pharmaceuticals-18-00262"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Riecke</surname><given-names>K.</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>V.</given-names></name>
<name><surname>Neunh&#x000f6;ffer</surname><given-names>T.</given-names></name>
<name><surname>Park-Simon</surname><given-names>T.-W.</given-names></name>
<name><surname>Weide</surname><given-names>R.</given-names></name>
<name><surname>Polasik</surname><given-names>A.</given-names></name>
<name><surname>Schmidt</surname><given-names>M.</given-names></name>
<name><surname>Puppe</surname><given-names>J.</given-names></name>
<name><surname>Mundhenke</surname><given-names>C.</given-names></name>
<name><surname>L&#x000fc;bbe</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Long-Term Survival of Breast Cancer Patients with Brain Metastases: Subanalysis of the BMBC Registry</article-title><source>ESMO Open</source><year>2023</year><volume>8</volume><fpage>101213</fpage><pub-id pub-id-type="doi">10.1016/j.esmoop.2023.101213</pub-id><pub-id pub-id-type="pmid">37075697</pub-id>
</element-citation></ref><ref id="B2-pharmaceuticals-18-00262"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Avila</surname><given-names>J.</given-names></name>
<name><surname>Leone</surname><given-names>J.</given-names></name>
<name><surname>Vallejo</surname><given-names>C.T.</given-names></name>
<name><surname>Lin</surname><given-names>N.U.</given-names></name>
<name><surname>Leone</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Survival Analysis of Patients with Brain Metastases at Initial Breast Cancer Diagnosis over the Last Decade</article-title><source>Breast Cancer Res. Treat.</source><year>2024</year><volume>205</volume><fpage>579</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1007/s10549-024-07290-1</pub-id><pub-id pub-id-type="pmid">38453783</pub-id>
</element-citation></ref><ref id="B3-pharmaceuticals-18-00262"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lockman</surname><given-names>P.R.</given-names></name>
<name><surname>Mittapalli</surname><given-names>R.K.</given-names></name>
<name><surname>Taskar</surname><given-names>K.S.</given-names></name>
<name><surname>Rudraraju</surname><given-names>V.</given-names></name>
<name><surname>Gril</surname><given-names>B.</given-names></name>
<name><surname>Bohn</surname><given-names>K.A.</given-names></name>
<name><surname>Adkins</surname><given-names>C.E.</given-names></name>
<name><surname>Roberts</surname><given-names>A.</given-names></name>
<name><surname>Thorsheim</surname><given-names>H.R.</given-names></name>
<name><surname>Gaasch</surname><given-names>J.A.</given-names></name>
<etal/>
</person-group><article-title>Heterogeneous Blood&#x02013;Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer</article-title><source>Clin. Cancer Res.</source><year>2010</year><volume>16</volume><fpage>5664</fpage><lpage>5678</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-1564</pub-id><pub-id pub-id-type="pmid">20829328</pub-id>
</element-citation></ref><ref id="B4-pharmaceuticals-18-00262"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cust&#x000f3;dio-Santos</surname><given-names>T.</given-names></name>
<name><surname>Videira</surname><given-names>M.</given-names></name>
<name><surname>Brito</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Brain Metastasization of Breast Cancer</article-title><source>Biochim. Biophys. Acta BBA Rev. Cancer</source><year>2017</year><volume>1868</volume><fpage>132</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2017.03.004</pub-id></element-citation></ref><ref id="B5-pharmaceuticals-18-00262"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>B.P.</given-names></name>
</person-group><article-title>Epithelial-Mesenchymal Transition in Breast Cancer Progression and Metastasis</article-title><source>Chin. J. Cancer</source><year>2011</year><volume>30</volume><fpage>603</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.5732/cjc.011.10226</pub-id><pub-id pub-id-type="pmid">21880181</pub-id>
</element-citation></ref><ref id="B6-pharmaceuticals-18-00262"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Espinosa Neira</surname><given-names>R.</given-names></name>
<name><surname>Salazar</surname><given-names>E.P.</given-names></name>
</person-group><article-title>Native Type IV Collagen Induces an Epithelial to Mesenchymal Transition-like Process in Mammary Epithelial Cells MCF10A</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2012</year><volume>44</volume><fpage>2194</fpage><lpage>2203</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2012.08.018</pub-id><pub-id pub-id-type="pmid">22981734</pub-id>
</element-citation></ref><ref id="B7-pharmaceuticals-18-00262"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ota</surname><given-names>I.</given-names></name>
<name><surname>Li</surname><given-names>X.-Y.</given-names></name>
<name><surname>Hu</surname><given-names>Y.</given-names></name>
<name><surname>Weiss</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Induction of a MT1-MMP and MT2-MMP-Dependent Basement Membrane Transmigration Program in Cancer Cells by Snail1</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>20318</fpage><lpage>20323</lpage><pub-id pub-id-type="doi">10.1073/pnas.0910962106</pub-id><pub-id pub-id-type="pmid">19915148</pub-id>
</element-citation></ref><ref id="B8-pharmaceuticals-18-00262"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harney</surname><given-names>A.S.</given-names></name>
<name><surname>Arwert</surname><given-names>E.N.</given-names></name>
<name><surname>Entenberg</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Guo</surname><given-names>P.</given-names></name>
<name><surname>Qian</surname><given-names>B.-Z.</given-names></name>
<name><surname>Oktay</surname><given-names>M.H.</given-names></name>
<name><surname>Pollard</surname><given-names>J.W.</given-names></name>
<name><surname>Jones</surname><given-names>J.G.</given-names></name>
<name><surname>Condeelis</surname><given-names>J.S.</given-names></name>
</person-group><article-title>Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi Macrophage&#x02013;Derived VEGFA</article-title><source>Cancer Discov.</source><year>2015</year><volume>5</volume><fpage>932</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0012</pub-id><pub-id pub-id-type="pmid">26269515</pub-id>
</element-citation></ref><ref id="B9-pharmaceuticals-18-00262"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bol&#x000f3;s</surname><given-names>V.</given-names></name>
<name><surname>Mira</surname><given-names>E.</given-names></name>
<name><surname>Mart&#x000ed;nez-Poveda</surname><given-names>B.</given-names></name>
<name><surname>Lux&#x000e1;n</surname><given-names>G.</given-names></name>
<name><surname>Ca&#x000f1;amero</surname><given-names>M.</given-names></name>
<name><surname>Mart&#x000ed;nez-A</surname><given-names>C.</given-names></name>
<name><surname>Ma&#x000f1;es</surname><given-names>S.</given-names></name>
<name><surname>De La Pompa</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Notch Activation Stimulates Migration of Breast Cancer Cells and Promotes Tumor Growth</article-title><source>Breast Cancer Res.</source><year>2013</year><volume>15</volume><fpage>R54</fpage><pub-id pub-id-type="doi">10.1186/bcr3447</pub-id><pub-id pub-id-type="pmid">23826634</pub-id>
</element-citation></ref><ref id="B10-pharmaceuticals-18-00262"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilhelm</surname><given-names>I.</given-names></name>
<name><surname>Moln&#x000e1;r</surname><given-names>J.</given-names></name>
<name><surname>Fazakas</surname><given-names>C.</given-names></name>
<name><surname>Hask&#x000f3;</surname><given-names>J.</given-names></name>
<name><surname>Krizbai</surname><given-names>I.A.</given-names></name>
</person-group><article-title>Role of the Blood-Brain Barrier in the Formation of Brain Metastases</article-title><source>Int. J. Mol. Sci.</source><year>2013</year><volume>14</volume><elocation-id>1383</elocation-id><pub-id pub-id-type="doi">10.3390/ijms14011383</pub-id><pub-id pub-id-type="pmid">23344048</pub-id>
</element-citation></ref><ref id="B11-pharmaceuticals-18-00262"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liebner</surname><given-names>S.</given-names></name>
<name><surname>Dijkhuizen</surname><given-names>R.M.</given-names></name>
<name><surname>Reiss</surname><given-names>Y.</given-names></name>
<name><surname>Plate</surname><given-names>K.H.</given-names></name>
<name><surname>Agalliu</surname><given-names>D.</given-names></name>
<name><surname>Constantin</surname><given-names>G.</given-names></name>
</person-group><article-title>Functional Morphology of the Blood&#x02013;Brain Barrier in Health and Disease</article-title><source>Acta Neuropathol</source><year>2018</year><volume>135</volume><fpage>311</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1007/s00401-018-1815-1</pub-id><pub-id pub-id-type="pmid">29411111</pub-id>
</element-citation></ref><ref id="B12-pharmaceuticals-18-00262"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lorger</surname><given-names>M.</given-names></name>
<name><surname>Lee</surname><given-names>H.</given-names></name>
<name><surname>Forsyth</surname><given-names>J.S.</given-names></name>
<name><surname>Felding-Habermann</surname><given-names>B.</given-names></name>
</person-group><article-title>Comparison of in Vitro and in Vivo Approaches to Studying Brain Colonization by Breast Cancer Cells</article-title><source>J. Neuro-Oncol.</source><year>2011</year><volume>104</volume><fpage>689</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1007/s11060-011-0550-4</pub-id><pub-id pub-id-type="pmid">21359851</pub-id>
</element-citation></ref><ref id="B13-pharmaceuticals-18-00262"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lorger</surname><given-names>M.</given-names></name>
<name><surname>Felding-Habermann</surname><given-names>B.</given-names></name>
</person-group><article-title>Capturing Changes in the Brain Microenvironment during Initial Steps of Breast Cancer Brain Metastasis</article-title><source>Am. J. Pathol.</source><year>2010</year><volume>176</volume><fpage>2958</fpage><lpage>2971</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2010.090838</pub-id><pub-id pub-id-type="pmid">20382702</pub-id>
</element-citation></ref><ref id="B14-pharmaceuticals-18-00262"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sevenich</surname><given-names>L.</given-names></name>
<name><surname>Bowman</surname><given-names>R.L.</given-names></name>
<name><surname>Mason</surname><given-names>S.D.</given-names></name>
<name><surname>Quail</surname><given-names>D.F.</given-names></name>
<name><surname>Rapaport</surname><given-names>F.</given-names></name>
<name><surname>Elie</surname><given-names>B.T.</given-names></name>
<name><surname>Brogi</surname><given-names>E.</given-names></name>
<name><surname>Brastianos</surname><given-names>P.K.</given-names></name>
<name><surname>Hahn</surname><given-names>W.C.</given-names></name>
<name><surname>Holsinger</surname><given-names>L.J.</given-names></name>
<etal/>
</person-group><article-title>Analysis of Tumour- and Stroma-Supplied Proteolytic Networks Reveals a Brain-Metastasis-Promoting Role for Cathepsin S</article-title><source>Nat. Cell Biol.</source><year>2014</year><volume>16</volume><fpage>876</fpage><lpage>888</lpage><pub-id pub-id-type="doi">10.1038/ncb3011</pub-id><pub-id pub-id-type="pmid">25086747</pub-id>
</element-citation></ref><ref id="B15-pharmaceuticals-18-00262"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Steeg</surname><given-names>P.S.</given-names></name>
</person-group><article-title>The Blood&#x02013;Tumour Barrier in Cancer Biology and Therapy</article-title><source>Nat. Reviews. Clin. Oncol.</source><year>2021</year><volume>18</volume><fpage>696</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1038/s41571-021-00529-6</pub-id></element-citation></ref><ref id="B16-pharmaceuticals-18-00262"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Winkler</surname><given-names>E.A.</given-names></name>
<name><surname>Bell</surname><given-names>R.D.</given-names></name>
<name><surname>Zlokovic</surname><given-names>B.V.</given-names></name>
</person-group><article-title>Central Nervous System Pericytes in Health and Disease</article-title><source>Nat. Neurosci.</source><year>2011</year><volume>14</volume><fpage>1398</fpage><lpage>1405</lpage><pub-id pub-id-type="doi">10.1038/nn.2946</pub-id><pub-id pub-id-type="pmid">22030551</pub-id>
</element-citation></ref><ref id="B17-pharmaceuticals-18-00262"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beeghly</surname><given-names>G.F.</given-names></name>
<name><surname>Amofa</surname><given-names>K.Y.</given-names></name>
<name><surname>Fischbach</surname><given-names>C.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
</person-group><article-title>Regulation of Tumor Invasion by the Physical Microenvironment: Lessons from Breast and Brain Cancer</article-title><source>Annu. Rev. Biomed. Eng.</source><year>2022</year><volume>24</volume><fpage>29</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1146/annurev-bioeng-110220-115419</pub-id><pub-id pub-id-type="pmid">35119915</pub-id>
</element-citation></ref><ref id="B18-pharmaceuticals-18-00262"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>Q.</given-names></name>
<name><surname>Guo</surname><given-names>P.</given-names></name>
<name><surname>Kruh</surname><given-names>G.D.</given-names></name>
<name><surname>Vicini</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Gallo</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Predicting Human Tumor Drug Concentrations from a Preclinical Pharmacokinetic Model of Temozolomide Brain Disposition</article-title><source>Clin. Cancer Res.</source><year>2007</year><volume>13</volume><fpage>4271</fpage><lpage>4279</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-0658</pub-id><pub-id pub-id-type="pmid">17634557</pub-id>
</element-citation></ref><ref id="B19-pharmaceuticals-18-00262"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cao</surname><given-names>K.I.</given-names></name>
<name><surname>Lebas</surname><given-names>N.</given-names></name>
<name><surname>Gerber</surname><given-names>S.</given-names></name>
<name><surname>Levy</surname><given-names>C.</given-names></name>
<name><surname>Le Scodan</surname><given-names>R.</given-names></name>
<name><surname>Bourgier</surname><given-names>C.</given-names></name>
<name><surname>Pierga</surname><given-names>J.-Y.</given-names></name>
<name><surname>Gobillion</surname><given-names>A.</given-names></name>
<name><surname>Savignoni</surname><given-names>A.</given-names></name>
<name><surname>Kirova</surname><given-names>Y.M.</given-names></name>
</person-group><article-title>Phase II Randomized Study of Whole-Brain Radiation Therapy with or without Concurrent Temozolomide for Brain Metastases from Breast Cancer</article-title><source>Ann. Oncol.</source><year>2015</year><volume>26</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu488</pub-id><pub-id pub-id-type="pmid">25355723</pub-id>
</element-citation></ref><ref id="B20-pharmaceuticals-18-00262"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gaedcke</surname><given-names>J.</given-names></name>
<name><surname>Traub</surname><given-names>F.</given-names></name>
<name><surname>Milde</surname><given-names>S.</given-names></name>
<name><surname>Wilkens</surname><given-names>L.</given-names></name>
<name><surname>Stan</surname><given-names>A.</given-names></name>
<name><surname>Ostertag</surname><given-names>H.</given-names></name>
<name><surname>Christgen</surname><given-names>M.</given-names></name>
<name><surname>von Wasielewski</surname><given-names>R.</given-names></name>
<name><surname>Kreipe</surname><given-names>H.H.</given-names></name>
</person-group><article-title>Predominance of the Basal Type and HER-2/Neu Type in Brain Metastasis from Breast Cancer</article-title><source>Mod. Pathol.</source><year>2007</year><volume>20</volume><fpage>864</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1038/modpathol.3800830</pub-id><pub-id pub-id-type="pmid">17541441</pub-id>
</element-citation></ref><ref id="B21-pharmaceuticals-18-00262"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tomasik</surname><given-names>B.</given-names></name>
<name><surname>Bie&#x00144;kowski</surname><given-names>M.</given-names></name>
<name><surname>G&#x000f3;rska</surname><given-names>Z.</given-names></name>
<name><surname>Gutowska</surname><given-names>K.</given-names></name>
<name><surname>Kumi&#x00119;ga</surname><given-names>P.</given-names></name>
<name><surname>Jassem</surname><given-names>J.</given-names></name>
<name><surname>Duchnowska</surname><given-names>R.</given-names></name>
</person-group><article-title>Molecular Aspects of Brain Metastases in Breast Cancer</article-title><source>Cancer Treat. Rev.</source><year>2023</year><volume>114</volume><fpage>102521</fpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2023.102521</pub-id><pub-id pub-id-type="pmid">36736124</pub-id>
</element-citation></ref><ref id="B22-pharmaceuticals-18-00262"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Hoffmann</surname><given-names>A.D.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
</person-group><article-title>Organotropism: New Insights into Molecular Mechanisms of Breast Cancer Metastasis</article-title><source>NPJ Precis. Onc.</source><year>2018</year><volume>2</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1038/s41698-018-0047-0</pub-id><pub-id pub-id-type="pmid">29872722</pub-id>
</element-citation></ref><ref id="B23-pharmaceuticals-18-00262"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Da Silva</surname><given-names>L.</given-names></name>
<name><surname>Simpson</surname><given-names>P.T.</given-names></name>
<name><surname>Smart</surname><given-names>C.E.</given-names></name>
<name><surname>Cocciardi</surname><given-names>S.</given-names></name>
<name><surname>Waddell</surname><given-names>N.</given-names></name>
<name><surname>Lane</surname><given-names>A.</given-names></name>
<name><surname>Morrison</surname><given-names>B.J.</given-names></name>
<name><surname>Vargas</surname><given-names>A.C.</given-names></name>
<name><surname>Healey</surname><given-names>S.</given-names></name>
<name><surname>Beesley</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>HER3 and Downstream Pathways Are Involved in Colonization of Brain Metastases from Breast Cancer</article-title><source>Breast Cancer Res.</source><year>2010</year><volume>12</volume><fpage>R46</fpage><pub-id pub-id-type="doi">10.1186/bcr2603</pub-id><pub-id pub-id-type="pmid">20604919</pub-id>
</element-citation></ref><ref id="B24-pharmaceuticals-18-00262"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raghav</surname><given-names>K.P.</given-names></name>
<name><surname>Moasser</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Molecular Pathways and Mechanisms of HER2 in Cancer Therapy</article-title><source>Clin. Cancer Res.</source><year>2022</year><volume>29</volume><fpage>2351</fpage><lpage>2361</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-22-0283</pub-id><pub-id pub-id-type="pmid">36574481</pub-id>
</element-citation></ref><ref id="B25-pharmaceuticals-18-00262"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Slamon</surname><given-names>D.J.</given-names></name>
<name><surname>Leyland-Jones</surname><given-names>B.</given-names></name>
<name><surname>Shak</surname><given-names>S.</given-names></name>
<name><surname>Fuchs</surname><given-names>H.</given-names></name>
<name><surname>Paton</surname><given-names>V.</given-names></name>
<name><surname>Bajamonde</surname><given-names>A.</given-names></name>
<name><surname>Fleming</surname><given-names>T.</given-names></name>
<name><surname>Eiermann</surname><given-names>W.</given-names></name>
<name><surname>Wolter</surname><given-names>J.</given-names></name>
<name><surname>Pegram</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2</article-title><source>N. Engl. J. Med.</source><year>2001</year><volume>344</volume><fpage>783</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1056/NEJM200103153441101</pub-id><pub-id pub-id-type="pmid">11248153</pub-id>
</element-citation></ref><ref id="B26-pharmaceuticals-18-00262"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Franklin</surname><given-names>M.C.</given-names></name>
<name><surname>Carey</surname><given-names>K.D.</given-names></name>
<name><surname>Vajdos</surname><given-names>F.F.</given-names></name>
<name><surname>Leahy</surname><given-names>D.J.</given-names></name>
<name><surname>de Vos</surname><given-names>A.M.</given-names></name>
<name><surname>Sliwkowski</surname><given-names>M.X.</given-names></name>
</person-group><article-title>Insights into ErbB Signaling from the Structure of the ErbB2-Pertuzumab Complex</article-title><source>Cancer Cell</source><year>2004</year><volume>5</volume><fpage>317</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/S1535-6108(04)00083-2</pub-id><pub-id pub-id-type="pmid">15093539</pub-id>
</element-citation></ref><ref id="B27-pharmaceuticals-18-00262"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Verma</surname><given-names>S.</given-names></name>
<name><surname>Miles</surname><given-names>D.</given-names></name>
<name><surname>Gianni</surname><given-names>L.</given-names></name>
<name><surname>Krop</surname><given-names>I.E.</given-names></name>
<name><surname>Welslau</surname><given-names>M.</given-names></name>
<name><surname>Baselga</surname><given-names>J.</given-names></name>
<name><surname>Pegram</surname><given-names>M.</given-names></name>
<name><surname>Oh</surname><given-names>D.-Y.</given-names></name>
<name><surname>Di&#x000e9;ras</surname><given-names>V.</given-names></name>
<name><surname>Guardino</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer</article-title><source>N. Engl. J. Med.</source><year>2012</year><volume>367</volume><fpage>1783</fpage><lpage>1791</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1209124</pub-id><pub-id pub-id-type="pmid">23020162</pub-id>
</element-citation></ref><ref id="B28-pharmaceuticals-18-00262"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ogitani</surname><given-names>Y.</given-names></name>
<name><surname>Aida</surname><given-names>T.</given-names></name>
<name><surname>Hagihara</surname><given-names>K.</given-names></name>
<name><surname>Yamaguchi</surname><given-names>J.</given-names></name>
<name><surname>Ishii</surname><given-names>C.</given-names></name>
<name><surname>Harada</surname><given-names>N.</given-names></name>
<name><surname>Soma</surname><given-names>M.</given-names></name>
<name><surname>Okamoto</surname><given-names>H.</given-names></name>
<name><surname>Oitate</surname><given-names>M.</given-names></name>
<name><surname>Arakawa</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1</article-title><source>Clin. Cancer Res.</source><year>2016</year><volume>22</volume><fpage>5097</fpage><lpage>5108</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2822</pub-id><pub-id pub-id-type="pmid">27026201</pub-id>
</element-citation></ref><ref id="B29-pharmaceuticals-18-00262"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murthy</surname><given-names>R.K.</given-names></name>
<name><surname>Loi</surname><given-names>S.</given-names></name>
<name><surname>Okines</surname><given-names>A.</given-names></name>
<name><surname>Paplomata</surname><given-names>E.</given-names></name>
<name><surname>Hamilton</surname><given-names>E.</given-names></name>
<name><surname>Hurvitz</surname><given-names>S.A.</given-names></name>
<name><surname>Lin</surname><given-names>N.U.</given-names></name>
<name><surname>Borges</surname><given-names>V.</given-names></name>
<name><surname>Abramson</surname><given-names>V.</given-names></name>
<name><surname>Anders</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>597</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1914609</pub-id><pub-id pub-id-type="pmid">31825569</pub-id>
</element-citation></ref><ref id="B30-pharmaceuticals-18-00262"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Geyer</surname><given-names>C.E.</given-names></name>
<name><surname>Forster</surname><given-names>J.</given-names></name>
<name><surname>Lindquist</surname><given-names>D.</given-names></name>
<name><surname>Chan</surname><given-names>S.</given-names></name>
<name><surname>Romieu</surname><given-names>C.G.</given-names></name>
<name><surname>Pienkowski</surname><given-names>T.</given-names></name>
<name><surname>Jagiello-Gruszfeld</surname><given-names>A.</given-names></name>
<name><surname>Crown</surname><given-names>J.</given-names></name>
<name><surname>Chan</surname><given-names>A.</given-names></name>
<name><surname>Kaufman</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer</article-title><source>N. Engl. J. Med.</source><year>2006</year><volume>355</volume><fpage>2733</fpage><lpage>2743</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa064320</pub-id><pub-id pub-id-type="pmid">17192538</pub-id>
</element-citation></ref><ref id="B31-pharmaceuticals-18-00262"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ciruelos</surname><given-names>E.</given-names></name>
<name><surname>Villagrasa</surname><given-names>P.</given-names></name>
<name><surname>Pascual</surname><given-names>T.</given-names></name>
<name><surname>Oliveira</surname><given-names>M.</given-names></name>
<name><surname>Pernas</surname><given-names>S.</given-names></name>
<name><surname>Par&#x000e9;</surname><given-names>L.</given-names></name>
<name><surname>Escriv&#x000e1;-de-Roman&#x000ed;</surname><given-names>S.</given-names></name>
<name><surname>Manso</surname><given-names>L.</given-names></name>
<name><surname>Adamo</surname><given-names>B.</given-names></name>
<name><surname>Mart&#x000ed;nez</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial</article-title><source>Clin. Cancer Res.</source><year>2020</year><volume>26</volume><fpage>5820</fpage><lpage>5829</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-0844</pub-id><pub-id pub-id-type="pmid">32938620</pub-id>
</element-citation></ref><ref id="B32-pharmaceuticals-18-00262"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Swain</surname><given-names>S.M.</given-names></name>
<name><surname>Miles</surname><given-names>D.</given-names></name>
<name><surname>Kim</surname><given-names>S.-B.</given-names></name>
<name><surname>Im</surname><given-names>Y.-H.</given-names></name>
<name><surname>Im</surname><given-names>S.-A.</given-names></name>
<name><surname>Semiglazov</surname><given-names>V.</given-names></name>
<name><surname>Ciruelos</surname><given-names>E.</given-names></name>
<name><surname>Schneeweiss</surname><given-names>A.</given-names></name>
<name><surname>Loi</surname><given-names>S.</given-names></name>
<name><surname>Monturus</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer (CLEOPATRA): End-of-Study Results from a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Study</article-title><source>Lancet. Oncol.</source><year>2020</year><volume>21</volume><fpage>519</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(19)30863-0</pub-id><pub-id pub-id-type="pmid">32171426</pub-id>
</element-citation></ref><ref id="B33-pharmaceuticals-18-00262"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takano</surname><given-names>T.</given-names></name>
<name><surname>Kimura</surname><given-names>H.</given-names></name>
<name><surname>Nishio</surname><given-names>K.</given-names></name>
<name><surname>Yamanaka</surname><given-names>T.</given-names></name>
<name><surname>Ito</surname><given-names>Y.</given-names></name>
<name><surname>Fukuoka</surname><given-names>J.</given-names></name>
<name><surname>Tsurutani</surname><given-names>J.</given-names></name>
<name><surname>Shigeoka</surname><given-names>Y.</given-names></name>
<name><surname>Uehara</surname><given-names>M.</given-names></name>
<name><surname>Sato</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>WJOG6110B (ELTOP): Randomized Phase II Trial Comparing Trastuzumab plus Capecitabine (HX) and Lapatinib plus Capecitabine (LX) in HER2-Positive Metastatic Breast Cancer Patients Previously Treated with Trastuzumab and Taxanes</article-title><source>J. Clin. Oncol.</source><year>2019</year><volume>37</volume><fpage>1081</fpage><lpage>1089</lpage><pub-id pub-id-type="doi">10.1200/jco.2012.30.15_suppl.tps659</pub-id><pub-id pub-id-type="pmid">30860945</pub-id>
</element-citation></ref><ref id="B34-pharmaceuticals-18-00262"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Freedman</surname><given-names>R.A.</given-names></name>
<name><surname>Gelman</surname><given-names>R.S.</given-names></name>
<name><surname>Anders</surname><given-names>C.K.</given-names></name>
<name><surname>Melisko</surname><given-names>M.E.</given-names></name>
<name><surname>Parsons</surname><given-names>H.A.</given-names></name>
<name><surname>Cropp</surname><given-names>A.M.</given-names></name>
<name><surname>Silvestri</surname><given-names>K.</given-names></name>
<name><surname>Cotter</surname><given-names>C.M.</given-names></name>
<name><surname>Componeschi</surname><given-names>K.P.</given-names></name>
<name><surname>Marte</surname><given-names>J.M.</given-names></name>
<etal/>
</person-group><article-title>TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2&#x02013;Positive Breast Cancer and Brain Metastases</article-title><source>J. Clin. Oncol.</source><year>2019</year><volume>37</volume><fpage>1081</fpage><lpage>1089</lpage><pub-id pub-id-type="doi">10.1200/JCO.18.01511</pub-id><pub-id pub-id-type="pmid">30860945</pub-id>
</element-citation></ref><ref id="B35-pharmaceuticals-18-00262"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yan</surname><given-names>M.</given-names></name>
<name><surname>Ouyang</surname><given-names>Q.</given-names></name>
<name><surname>Sun</surname><given-names>T.</given-names></name>
<name><surname>Niu</surname><given-names>L.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Song</surname><given-names>Y.</given-names></name>
<name><surname>Hao</surname><given-names>C.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Orlandi</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Pyrotinib plus Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases (PERMEATE): A Multicentre, Single-Arm, Two-Cohort, Phase 2 Trial</article-title><source>Lancet Oncol.</source><year>2022</year><volume>23</volume><fpage>353</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(21)00716-6</pub-id><pub-id pub-id-type="pmid">35085506</pub-id>
</element-citation></ref><ref id="B36-pharmaceuticals-18-00262"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Curigliano</surname><given-names>G.</given-names></name>
<name><surname>Mueller</surname><given-names>V.</given-names></name>
<name><surname>Borges</surname><given-names>V.</given-names></name>
<name><surname>Hamilton</surname><given-names>E.</given-names></name>
<name><surname>Hurvitz</surname><given-names>S.</given-names></name>
<name><surname>Loi</surname><given-names>S.</given-names></name>
<name><surname>Murthy</surname><given-names>R.</given-names></name>
<name><surname>Okines</surname><given-names>A.</given-names></name>
<name><surname>Paplomata</surname><given-names>E.</given-names></name>
<name><surname>Cameron</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Tucatinib versus Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis</article-title><source>Ann. Oncol.</source><year>2021</year><volume>33</volume><fpage>321</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2021.12.005</pub-id><pub-id pub-id-type="pmid">34954044</pub-id>
</element-citation></ref><ref id="B37-pharmaceuticals-18-00262"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bartsch</surname><given-names>R.</given-names></name>
<name><surname>Berghoff</surname><given-names>A.S.</given-names></name>
<name><surname>Furtner</surname><given-names>J.</given-names></name>
<name><surname>Marhold</surname><given-names>M.</given-names></name>
<name><surname>Bergen</surname><given-names>E.S.</given-names></name>
<name><surname>Roider-Schur</surname><given-names>S.</given-names></name>
<name><surname>Starzer</surname><given-names>A.M.</given-names></name>
<name><surname>Forstner</surname><given-names>H.</given-names></name>
<name><surname>Rottenmanner</surname><given-names>B.</given-names></name>
<name><surname>Dieckmann</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Trastuzumab Deruxtecan in HER2-Positive Breast Cancer with Brain Metastases: A Single-Arm, Phase 2 Trial</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>1840</fpage><lpage>1847</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01935-8</pub-id><pub-id pub-id-type="pmid">35941372</pub-id>
</element-citation></ref><ref id="B38-pharmaceuticals-18-00262"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hurvitz</surname><given-names>S.A.</given-names></name>
<name><surname>Hegg</surname><given-names>R.</given-names></name>
<name><surname>Chung</surname><given-names>W.-P.</given-names></name>
<name><surname>Im</surname><given-names>S.-A.</given-names></name>
<name><surname>Jacot</surname><given-names>W.</given-names></name>
<name><surname>Ganju</surname><given-names>V.</given-names></name>
<name><surname>Chiu</surname><given-names>J.W.Y.</given-names></name>
<name><surname>Xu</surname><given-names>B.</given-names></name>
<name><surname>Hamilton</surname><given-names>E.</given-names></name>
<name><surname>Madhusudan</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results from DESTINY-Breast03, a Randomised, Open-Label, Phase 3 Trial</article-title><source>Lancet</source><year>2022</year><volume>401</volume><fpage>105</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)02420-5</pub-id><pub-id pub-id-type="pmid">36495879</pub-id>
</element-citation></ref><ref id="B39-pharmaceuticals-18-00262"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>Y.H.</given-names></name>
<name><surname>Park</surname><given-names>M.J.</given-names></name>
<name><surname>Ji</surname><given-names>S.H.</given-names></name>
<name><surname>Yi</surname><given-names>S.Y.</given-names></name>
<name><surname>Lim</surname><given-names>D.H.</given-names></name>
<name><surname>Nam</surname><given-names>D.H.</given-names></name>
<name><surname>Lee</surname><given-names>J.-I.</given-names></name>
<name><surname>Park</surname><given-names>W.</given-names></name>
<name><surname>Choi</surname><given-names>D.H.</given-names></name>
<name><surname>Huh</surname><given-names>S.J.</given-names></name>
<etal/>
</person-group><article-title>Trastuzumab Treatment Improves Brain Metastasis Outcomes through Control and Durable Prolongation of Systemic Extracranial Disease in HER2-Overexpressing Breast Cancer Patients</article-title><source>Br. J. Cancer</source><year>2009</year><volume>100</volume><fpage>894</fpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6604941</pub-id><pub-id pub-id-type="pmid">19240719</pub-id>
</element-citation></ref><ref id="B40-pharmaceuticals-18-00262"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Swain</surname><given-names>S.M.</given-names></name>
<name><surname>Baselga</surname><given-names>J.</given-names></name>
<name><surname>Miles</surname><given-names>D.</given-names></name>
<name><surname>Im</surname><given-names>Y.-H.</given-names></name>
<name><surname>Quah</surname><given-names>C.</given-names></name>
<name><surname>Lee</surname><given-names>L.F.</given-names></name>
<name><surname>Cort&#x000e9;s</surname><given-names>J.</given-names></name>
</person-group><article-title>Incidence of Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer Treated with Pertuzumab, Trastuzumab, and Docetaxel: Results from the Randomized Phase III Study CLEOPATRA</article-title><source>Ann. Oncol.</source><year>2014</year><volume>25</volume><fpage>1116</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu133</pub-id><pub-id pub-id-type="pmid">24685829</pub-id>
</element-citation></ref><ref id="B41-pharmaceuticals-18-00262"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>N.U.</given-names></name>
<name><surname>Di&#x000e9;ras</surname><given-names>V.</given-names></name>
<name><surname>Paul</surname><given-names>D.</given-names></name>
<name><surname>Lossignol</surname><given-names>D.</given-names></name>
<name><surname>Christodoulou</surname><given-names>C.</given-names></name>
<name><surname>Stemmler</surname><given-names>H.-J.</given-names></name>
<name><surname>Roch&#x000e9;</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>M.C.</given-names></name>
<name><surname>Greil</surname><given-names>R.</given-names></name>
<name><surname>Ciruelos</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer</article-title><source>Clin. Cancer Res.</source><year>2009</year><volume>15</volume><fpage>1452</fpage><lpage>1459</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-1080</pub-id><pub-id pub-id-type="pmid">19228746</pub-id>
</element-citation></ref><ref id="B42-pharmaceuticals-18-00262"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bachelot</surname><given-names>T.</given-names></name>
<name><surname>Romieu</surname><given-names>G.</given-names></name>
<name><surname>Campone</surname><given-names>M.</given-names></name>
<name><surname>Di&#x000e9;ras</surname><given-names>V.</given-names></name>
<name><surname>Cropet</surname><given-names>C.</given-names></name>
<name><surname>Dalenc</surname><given-names>F.</given-names></name>
<name><surname>Jimenez</surname><given-names>M.</given-names></name>
<name><surname>Le Rhun</surname><given-names>E.</given-names></name>
<name><surname>Pierga</surname><given-names>J.-Y.</given-names></name>
<name><surname>Gon&#x000e7;alves</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Lapatinib plus Capecitabine in Patients with Previously Untreated Brain Metastases from HER2-Positive Metastatic Breast Cancer (LANDSCAPE): A Single-Group Phase 2 Study</article-title><source>Lancet Oncol.</source><year>2013</year><volume>14</volume><fpage>64</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(12)70432-1</pub-id><pub-id pub-id-type="pmid">23122784</pub-id>
</element-citation></ref><ref id="B43-pharmaceuticals-18-00262"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Meng</surname><given-names>J.</given-names></name>
<name><surname>Mei</surname><given-names>X.</given-names></name>
<name><surname>Mo</surname><given-names>M.</given-names></name>
<name><surname>Xiao</surname><given-names>Q.</given-names></name>
<name><surname>Han</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Shi</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Ma</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Brain Radiotherapy With Pyrotinib and Capecitabine in Patients With ERBB2-Positive Advanced Breast Cancer and Brain Metastases: A Nonrandomized Phase 2 Trial</article-title><source>JAMA Oncol.</source><year>2024</year><volume>10</volume><fpage>335</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2023.5791</pub-id><pub-id pub-id-type="pmid">38175627</pub-id>
</element-citation></ref><ref id="B44-pharmaceuticals-18-00262"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>N.U.</given-names></name>
<name><surname>Borges</surname><given-names>V.</given-names></name>
<name><surname>Anders</surname><given-names>C.</given-names></name>
<name><surname>Murthy</surname><given-names>R.K.</given-names></name>
<name><surname>Paplomata</surname><given-names>E.</given-names></name>
<name><surname>Hamilton</surname><given-names>E.</given-names></name>
<name><surname>Hurvitz</surname><given-names>S.</given-names></name>
<name><surname>Loi</surname><given-names>S.</given-names></name>
<name><surname>Okines</surname><given-names>A.</given-names></name>
<name><surname>Abramson</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial</article-title><source>J. Clin. Oncol.</source><year>2020</year><volume>38</volume><fpage>2610</fpage><pub-id pub-id-type="doi">10.1200/JCO.20.00775</pub-id><pub-id pub-id-type="pmid">32468955</pub-id>
</element-citation></ref><ref id="B45-pharmaceuticals-18-00262"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Epaillard</surname><given-names>N.</given-names></name>
<name><surname>Bassil</surname><given-names>J.</given-names></name>
<name><surname>Pistilli</surname><given-names>B.</given-names></name>
</person-group><article-title>Current Indications and Future Perspectives for Antibody-Drug Conjugates in Brain Metastases of Breast Cancer</article-title><source>Cancer Treat Rev.</source><year>2023</year><volume>119</volume><fpage>102597</fpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2023.102597</pub-id><pub-id pub-id-type="pmid">37454577</pub-id>
</element-citation></ref><ref id="B46-pharmaceuticals-18-00262"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lewis Phillips</surname><given-names>G.D.</given-names></name>
<name><surname>Li</surname><given-names>G.</given-names></name>
<name><surname>Dugger</surname><given-names>D.L.</given-names></name>
<name><surname>Crocker</surname><given-names>L.M.</given-names></name>
<name><surname>Parsons</surname><given-names>K.L.</given-names></name>
<name><surname>Mai</surname><given-names>E.</given-names></name>
<name><surname>Bl&#x000e4;ttler</surname><given-names>W.A.</given-names></name>
<name><surname>Lambert</surname><given-names>J.M.</given-names></name>
<name><surname>Chari</surname><given-names>R.V.J.</given-names></name>
<name><surname>Lutz</surname><given-names>R.J.</given-names></name>
<etal/>
</person-group><article-title>Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody&#x02013;Cytotoxic Drug Conjugate</article-title><source>Cancer Res.</source><year>2008</year><volume>68</volume><fpage>9280</fpage><lpage>9290</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-1776</pub-id><pub-id pub-id-type="pmid">19010901</pub-id>
</element-citation></ref><ref id="B47-pharmaceuticals-18-00262"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krop</surname><given-names>I.E.</given-names></name>
<name><surname>Lin</surname><given-names>N.U.</given-names></name>
<name><surname>Blackwell</surname><given-names>K.</given-names></name>
<name><surname>Guardino</surname><given-names>E.</given-names></name>
<name><surname>Huober</surname><given-names>J.</given-names></name>
<name><surname>Lu</surname><given-names>M.</given-names></name>
<name><surname>Miles</surname><given-names>D.</given-names></name>
<name><surname>Samant</surname><given-names>M.</given-names></name>
<name><surname>Welslau</surname><given-names>M.</given-names></name>
<name><surname>Di&#x000e9;ras</surname><given-names>V.</given-names></name>
</person-group><article-title>Trastuzumab Emtansine (T-DM1) versus Lapatinib plus Capecitabine in Patients with HER2-Positive Metastatic Breast Cancer and Central Nervous System Metastases: A Retrospective, Exploratory Analysis in EMILIA</article-title><source>Ann. Oncol.</source><year>2014</year><volume>26</volume><fpage>113</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu486</pub-id><pub-id pub-id-type="pmid">25355722</pub-id>
</element-citation></ref><ref id="B48-pharmaceuticals-18-00262"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jerusalem</surname><given-names>G.</given-names></name>
<name><surname>Park</surname><given-names>Y.H.</given-names></name>
<name><surname>Yamashita</surname><given-names>T.</given-names></name>
<name><surname>Hurvitz</surname><given-names>S.A.</given-names></name>
<name><surname>Modi</surname><given-names>S.</given-names></name>
<name><surname>Andre</surname><given-names>F.</given-names></name>
<name><surname>Krop</surname><given-names>I.E.</given-names></name>
<name><surname>Gonz&#x000e0;lez Farr&#x000e9;</surname><given-names>X.</given-names></name>
<name><surname>You</surname><given-names>B.</given-names></name>
<name><surname>Saura</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis</article-title><source>Cancer Discov.</source><year>2022</year><volume>12</volume><fpage>2754</fpage><lpage>2762</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-22-0837</pub-id><pub-id pub-id-type="pmid">36255231</pub-id>
</element-citation></ref><ref id="B49-pharmaceuticals-18-00262"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nam</surname><given-names>D.-H.</given-names></name>
<name><surname>Jeon</surname><given-names>H.-M.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>M.H.</given-names></name>
<name><surname>Lee</surname><given-names>Y.-J.</given-names></name>
<name><surname>Lee</surname><given-names>M.S.</given-names></name>
<name><surname>Kim</surname><given-names>H.</given-names></name>
<name><surname>Joo</surname><given-names>K.M.</given-names></name>
<name><surname>Lee</surname><given-names>D.-S.</given-names></name>
<name><surname>Price</surname><given-names>J.E.</given-names></name>
<etal/>
</person-group><article-title>Activation of Notch Signaling in a Xenograft Model of Brain Metastasis</article-title><source>Clin. Cancer Res.</source><year>2008</year><volume>14</volume><fpage>4059</fpage><lpage>4066</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-4039</pub-id><pub-id pub-id-type="pmid">18593982</pub-id>
</element-citation></ref><ref id="B50-pharmaceuticals-18-00262"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klemm</surname><given-names>F.</given-names></name>
<name><surname>Bleckmann</surname><given-names>A.</given-names></name>
<name><surname>Siam</surname><given-names>L.</given-names></name>
<name><surname>Chuang</surname><given-names>H.N.</given-names></name>
<name><surname>Rietk&#x000f6;tter</surname><given-names>E.</given-names></name>
<name><surname>Behme</surname><given-names>D.</given-names></name>
<name><surname>Schulz</surname><given-names>M.</given-names></name>
<name><surname>Schaffrinski</surname><given-names>M.</given-names></name>
<name><surname>Schindler</surname><given-names>S.</given-names></name>
<name><surname>Tr&#x000fc;mper</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>&#x003b2;-Catenin-Independent WNT Signaling in Basal-like Breast Cancer and Brain Metastasis</article-title><source>Carcinogenesis</source><year>2011</year><volume>32</volume><fpage>434</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgq269</pub-id><pub-id pub-id-type="pmid">21173432</pub-id>
</element-citation></ref><ref id="B51-pharmaceuticals-18-00262"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Farnie</surname><given-names>G.</given-names></name>
<name><surname>Clarke</surname><given-names>R.B.</given-names></name>
</person-group><article-title>Mammary Stem Cells and Breast Cancer&#x02014;Role of Notch Signalling</article-title><source>Stem. Cell Rev.</source><year>2007</year><volume>3</volume><fpage>169</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1007/s12015-007-0023-5</pub-id><pub-id pub-id-type="pmid">17873349</pub-id>
</element-citation></ref><ref id="B52-pharmaceuticals-18-00262"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dontu</surname><given-names>G.</given-names></name>
<name><surname>Jackson</surname><given-names>K.W.</given-names></name>
<name><surname>McNicholas</surname><given-names>E.</given-names></name>
<name><surname>Kawamura</surname><given-names>M.J.</given-names></name>
<name><surname>Abdallah</surname><given-names>W.M.</given-names></name>
<name><surname>Wicha</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Role of Notch Signaling in Cell-Fate Determination of Human Mammary Stem/Progenitor Cells</article-title><source>Breast Cancer Res.</source><year>2004</year><volume>6</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1186/bcr920</pub-id><pub-id pub-id-type="pmid">14680479</pub-id>
</element-citation></ref><ref id="B53-pharmaceuticals-18-00262"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roarty</surname><given-names>K.</given-names></name>
<name><surname>Pfefferle</surname><given-names>A.D.</given-names></name>
<name><surname>Creighton</surname><given-names>C.J.</given-names></name>
<name><surname>Perou</surname><given-names>C.M.</given-names></name>
<name><surname>Rosen</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Ror2-Mediated Alternative Wnt Signaling Regulates Cell Fate and Adhesion during Mammary Tumor Progression</article-title><source>Oncogene</source><year>2017</year><volume>36</volume><fpage>5958</fpage><lpage>5968</lpage><pub-id pub-id-type="doi">10.1038/onc.2017.206</pub-id><pub-id pub-id-type="pmid">28650466</pub-id>
</element-citation></ref><ref id="B54-pharmaceuticals-18-00262"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Menck</surname><given-names>K.</given-names></name>
<name><surname>Heinrichs</surname><given-names>S.</given-names></name>
<name><surname>Wlochowitz</surname><given-names>D.</given-names></name>
<name><surname>Sitte</surname><given-names>M.</given-names></name>
<name><surname>Noeding</surname><given-names>H.</given-names></name>
<name><surname>Janshoff</surname><given-names>A.</given-names></name>
<name><surname>Treiber</surname><given-names>H.</given-names></name>
<name><surname>Ruhwedel</surname><given-names>T.</given-names></name>
<name><surname>Schatlo</surname><given-names>B.</given-names></name>
<name><surname>Von Der Brelie</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>WNT11/ROR2 Signaling Is Associated with Tumor Invasion and Poor Survival in Breast Cancer</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2021</year><volume>40</volume><fpage>395</fpage><pub-id pub-id-type="doi">10.1186/s13046-021-02187-z</pub-id><pub-id pub-id-type="pmid">34911552</pub-id>
</element-citation></ref><ref id="B55-pharmaceuticals-18-00262"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>C.-H.</given-names></name>
<name><surname>Huang</surname><given-names>S.</given-names></name>
<name><surname>Fu</surname><given-names>Z.</given-names></name>
<name><surname>Tomita</surname><given-names>Y.</given-names></name>
<name><surname>Britton</surname><given-names>W.R.</given-names></name>
<name><surname>Cho</surname><given-names>S.S.</given-names></name>
<name><surname>Chen</surname><given-names>C.T.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Ma</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Wnt Signaling Activates MFSD2A to Suppress Vascular Endothelial Transcytosis and Maintain Blood-Retinal Barrier</article-title><source>Sci. Adv.</source><year>2020</year><volume>6</volume><fpage>eaba7457</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aba7457</pub-id><pub-id pub-id-type="pmid">32923627</pub-id>
</element-citation></ref><ref id="B56-pharmaceuticals-18-00262"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martin</surname><given-names>M.</given-names></name>
<name><surname>Vermeiren</surname><given-names>S.</given-names></name>
<name><surname>Bostaille</surname><given-names>N.</given-names></name>
<name><surname>Eubelen</surname><given-names>M.</given-names></name>
<name><surname>Spitzer</surname><given-names>D.</given-names></name>
<name><surname>Vermeersch</surname><given-names>M.</given-names></name>
<name><surname>Profaci</surname><given-names>C.P.</given-names></name>
<name><surname>Pozuelo</surname><given-names>E.</given-names></name>
<name><surname>Toussay</surname><given-names>X.</given-names></name>
<name><surname>Raman-Nair</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Engineered Wnt Ligands Enable Blood-Brain Barrier Repair in Neurological Disorders</article-title><source>Science</source><year>2022</year><volume>375</volume><fpage>eabm4459</fpage><pub-id pub-id-type="doi">10.1126/science.abm4459</pub-id><pub-id pub-id-type="pmid">35175798</pub-id>
</element-citation></ref><ref id="B57-pharmaceuticals-18-00262"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ben-Zvi</surname><given-names>A.</given-names></name>
<name><surname>Lacoste</surname><given-names>B.</given-names></name>
<name><surname>Kur</surname><given-names>E.</given-names></name>
<name><surname>Andreone</surname><given-names>B.J.</given-names></name>
<name><surname>Mayshar</surname><given-names>Y.</given-names></name>
<name><surname>Yan</surname><given-names>H.</given-names></name>
<name><surname>Gu</surname><given-names>C.</given-names></name>
</person-group><article-title>Mfsd2a Is Critical for the Formation and Function of the Blood&#x02013;Brain Barrier</article-title><source>Nature</source><year>2014</year><volume>509</volume><fpage>507</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1038/nature13324</pub-id><pub-id pub-id-type="pmid">24828040</pub-id>
</element-citation></ref><ref id="B58-pharmaceuticals-18-00262"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ju</surname><given-names>X.</given-names></name>
<name><surname>Miao</surname><given-names>T.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Ni</surname><given-names>J.</given-names></name>
<name><surname>Han</surname><given-names>L.</given-names></name>
</person-group><article-title>Overcoming Mfsd2a-Mediated Low Transcytosis to Boost Nanoparticle Delivery to Brain for Chemotherapy of Brain Metastases</article-title><source>Adv. Healthc. Mater.</source><year>2021</year><volume>10</volume><fpage>2001997</fpage><pub-id pub-id-type="doi">10.1002/adhm.202001997</pub-id><pub-id pub-id-type="pmid">33738958</pub-id>
</element-citation></ref><ref id="B59-pharmaceuticals-18-00262"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chung</surname><given-names>H.</given-names></name>
<name><surname>Jung</surname><given-names>Y.</given-names></name>
<name><surname>Shin</surname><given-names>D.-H.</given-names></name>
<name><surname>Lee</surname><given-names>J.-Y.</given-names></name>
<name><surname>Oh</surname><given-names>M.-Y.</given-names></name>
<name><surname>Kim</surname><given-names>H.-J.</given-names></name>
<name><surname>Jang</surname><given-names>K.S.</given-names></name>
<name><surname>Jeon</surname><given-names>S.J.</given-names></name>
<name><surname>Son</surname><given-names>K.H.</given-names></name>
<name><surname>Kong</surname><given-names>G.</given-names></name>
</person-group><article-title>Anticancer Effects of Wogonin in Both Estrogen Receptor-positive and -negative Human Breast Cancer Cell Lines in Vitro and in Nude Mice Xenografts</article-title><source>Int. J. Cancer</source><year>2007</year><volume>122</volume><fpage>816</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1002/ijc.23182</pub-id></element-citation></ref><ref id="B60-pharmaceuticals-18-00262"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tong</surname><given-names>Y.</given-names></name>
<name><surname>An</surname><given-names>P.</given-names></name>
<name><surname>Tang</surname><given-names>P.</given-names></name>
<name><surname>Mu</surname><given-names>R.</given-names></name>
<name><surname>Zeng</surname><given-names>Y.</given-names></name>
<name><surname>Sun</surname><given-names>H.</given-names></name>
<name><surname>Zhao</surname><given-names>M.</given-names></name>
<name><surname>Lv</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Han</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Suppressing Wnt Signaling of the Blood-tumor Barrier to Intensify Drug Delivery and Inhibit Lipogenesis of Brain Metastases</article-title><source>Acta Pharm. Sin. B</source><year>2024</year><volume>14</volume><fpage>2716</fpage><lpage>2731</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2024.03.024</pub-id><pub-id pub-id-type="pmid">38828148</pub-id>
</element-citation></ref><ref id="B61-pharmaceuticals-18-00262"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koo</surname><given-names>B.-K.</given-names></name>
<name><surname>van Es</surname><given-names>J.H.</given-names></name>
<name><surname>van den Born</surname><given-names>M.</given-names></name>
<name><surname>Clevers</surname><given-names>H.</given-names></name>
</person-group><article-title>Porcupine Inhibitor Suppresses Paracrine Wnt-Driven Growth of <italic toggle="yes">Rnf43;Znrf3</italic>-Mutant Neoplasia</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2015</year><volume>112</volume><fpage>7548</fpage><lpage>7550</lpage><pub-id pub-id-type="doi">10.1073/pnas.1508113112</pub-id><pub-id pub-id-type="pmid">26023187</pub-id>
</element-citation></ref><ref id="B62-pharmaceuticals-18-00262"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Moon</surname><given-names>J.</given-names></name>
<name><surname>Dodge</surname><given-names>M.E.</given-names></name>
<name><surname>Pan</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Hanson</surname><given-names>J.M.</given-names></name>
<name><surname>Tuladhar</surname><given-names>R.</given-names></name>
<name><surname>Ma</surname><given-names>Z.</given-names></name>
<name><surname>Shi</surname><given-names>H.</given-names></name>
<name><surname>Williams</surname><given-names>N.S.</given-names></name>
<etal/>
</person-group><article-title>The Development of Highly Potent Inhibitors for Porcupine</article-title><source>J. Med. Chem.</source><year>2013</year><volume>56</volume><fpage>2700</fpage><lpage>2704</lpage><pub-id pub-id-type="doi">10.1021/jm400159c</pub-id><pub-id pub-id-type="pmid">23477365</pub-id>
</element-citation></ref><ref id="B63-pharmaceuticals-18-00262"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Pan</surname><given-names>S.</given-names></name>
<name><surname>Hsieh</surname><given-names>M.H.</given-names></name>
<name><surname>Ng</surname><given-names>N.</given-names></name>
<name><surname>Sun</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Kasibhatla</surname><given-names>S.</given-names></name>
<name><surname>Schuller</surname><given-names>A.G.</given-names></name>
<name><surname>Li</surname><given-names>A.G.</given-names></name>
<name><surname>Cheng</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Targeting Wnt-Driven Cancer through the Inhibition of Porcupine by LGK974</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>20224</fpage><lpage>20229</lpage><pub-id pub-id-type="doi">10.1073/pnas.1314239110</pub-id><pub-id pub-id-type="pmid">24277854</pub-id>
</element-citation></ref><ref id="B64-pharmaceuticals-18-00262"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Song</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>Q.</given-names></name>
</person-group><article-title>Metastatic Heterogeneity of Breast Cancer: Molecular Mechanism and Potential Therapeutic Targets</article-title><source>Semin. Cancer Biol.</source><year>2020</year><volume>60</volume><fpage>14</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2019.08.012</pub-id><pub-id pub-id-type="pmid">31421262</pub-id>
</element-citation></ref><ref id="B65-pharmaceuticals-18-00262"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qiao</surname><given-names>X.</given-names></name>
<name><surname>Ma</surname><given-names>B.</given-names></name>
<name><surname>Sun</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>N.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Jia</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>C.</given-names></name>
</person-group><article-title>JAG1 Is Associated with the Prognosis and Metastasis in Breast Cancer</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><elocation-id>21986</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-26241-8</pub-id><pub-id pub-id-type="pmid">36539520</pub-id>
</element-citation></ref><ref id="B66-pharmaceuticals-18-00262"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xing</surname><given-names>F.</given-names></name>
<name><surname>Kobayashi</surname><given-names>A.</given-names></name>
<name><surname>Okuda</surname><given-names>H.</given-names></name>
<name><surname>Watabe</surname><given-names>M.</given-names></name>
<name><surname>Pai</surname><given-names>S.K.</given-names></name>
<name><surname>Pandey</surname><given-names>P.R.</given-names></name>
<name><surname>Hirota</surname><given-names>S.</given-names></name>
<name><surname>Wilber</surname><given-names>A.</given-names></name>
<name><surname>Mo</surname><given-names>Y.-Y.</given-names></name>
<name><surname>Moore</surname><given-names>B.E.</given-names></name>
<etal/>
</person-group><article-title>Reactive Astrocytes Promote the Metastatic Growth of Breast Cancer Stem-like Cells by Activating Notch Signalling in Brain</article-title><source>EMBO Mol. Med.</source><year>2013</year><volume>5</volume><fpage>384</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1002/emmm.201201623</pub-id><pub-id pub-id-type="pmid">23495140</pub-id>
</element-citation></ref><ref id="B67-pharmaceuticals-18-00262"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raub</surname><given-names>T.J.</given-names></name>
<name><surname>Wishart</surname><given-names>G.N.</given-names></name>
<name><surname>Kulanthaivel</surname><given-names>P.</given-names></name>
<name><surname>Staton</surname><given-names>B.A.</given-names></name>
<name><surname>Ajamie</surname><given-names>R.T.</given-names></name>
<name><surname>Sawada</surname><given-names>G.A.</given-names></name>
<name><surname>Gelbert</surname><given-names>L.M.</given-names></name>
<name><surname>Shannon</surname><given-names>H.E.</given-names></name>
<name><surname>Sanchez-Martinez</surname><given-names>C.</given-names></name>
<name><surname>De Dios</surname><given-names>A.</given-names></name>
</person-group><article-title>Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft</article-title><source>Drug Metab. Dispos.</source><year>2015</year><volume>43</volume><fpage>1360</fpage><lpage>1371</lpage><pub-id pub-id-type="doi">10.1124/dmd.114.062745</pub-id><pub-id pub-id-type="pmid">26149830</pub-id>
</element-citation></ref><ref id="B68-pharmaceuticals-18-00262"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>Q.</given-names></name>
<name><surname>Sicinska</surname><given-names>E.</given-names></name>
<name><surname>Geng</surname><given-names>Y.</given-names></name>
<name><surname>Ahnstr&#x000f6;m</surname><given-names>M.</given-names></name>
<name><surname>Zagozdzon</surname><given-names>A.</given-names></name>
<name><surname>Kong</surname><given-names>Y.</given-names></name>
<name><surname>Gardner</surname><given-names>H.</given-names></name>
<name><surname>Kiyokawa</surname><given-names>H.</given-names></name>
<name><surname>Harris</surname><given-names>L.N.</given-names></name>
<name><surname>St&#x000e5;l</surname><given-names>O.</given-names></name>
<etal/>
</person-group><article-title>Requirement for CDK4 Kinase Function in Breast Cancer</article-title><source>Cancer Cell</source><year>2006</year><volume>9</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2005.12.012</pub-id><pub-id pub-id-type="pmid">16413469</pub-id>
</element-citation></ref><ref id="B69-pharmaceuticals-18-00262"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chong</surname><given-names>Q.-Y.</given-names></name>
<name><surname>Kok</surname><given-names>Z.-H.</given-names></name>
<name><surname>Bui</surname><given-names>N.-L.-C.</given-names></name>
<name><surname>Xiang</surname><given-names>X.</given-names></name>
<name><surname>Wong</surname><given-names>A.L.-A.</given-names></name>
<name><surname>Yong</surname><given-names>W.-P.</given-names></name>
<name><surname>Sethi</surname><given-names>G.</given-names></name>
<name><surname>Lobie</surname><given-names>P.E.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Goh</surname><given-names>B.-C.</given-names></name>
</person-group><article-title>A Unique CDK4/6 Inhibitor: Current and Future Therapeutic Strategies of Abemaciclib</article-title><source>Pharmacol. Res.</source><year>2020</year><volume>156</volume><fpage>104686</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104686</pub-id><pub-id pub-id-type="pmid">32068118</pub-id>
</element-citation></ref><ref id="B70-pharmaceuticals-18-00262"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tolaney</surname><given-names>S.M.</given-names></name>
<name><surname>Sahebjam</surname><given-names>S.</given-names></name>
<name><surname>Le Rhun</surname><given-names>E.</given-names></name>
<name><surname>Bachelot</surname><given-names>T.</given-names></name>
<name><surname>Kabos</surname><given-names>P.</given-names></name>
<name><surname>Awada</surname><given-names>A.</given-names></name>
<name><surname>Yardley</surname><given-names>D.</given-names></name>
<name><surname>Chan</surname><given-names>A.</given-names></name>
<name><surname>Conte</surname><given-names>P.</given-names></name>
<name><surname>Di&#x000e9;ras</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor&#x02013;Positive Breast Cancer</article-title><source>Clin. Cancer Res.</source><year>2020</year><volume>26</volume><fpage>5310</fpage><lpage>5319</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-1764</pub-id><pub-id pub-id-type="pmid">32694159</pub-id>
</element-citation></ref><ref id="B71-pharmaceuticals-18-00262"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trerotola</surname><given-names>M.</given-names></name>
<name><surname>Cantanelli</surname><given-names>P.</given-names></name>
<name><surname>Guerra</surname><given-names>E.</given-names></name>
<name><surname>Tripaldi</surname><given-names>R.</given-names></name>
<name><surname>Aloisi</surname><given-names>A.L.</given-names></name>
<name><surname>Bonasera</surname><given-names>V.</given-names></name>
<name><surname>Lattanzio</surname><given-names>R.</given-names></name>
<name><surname>de Lange</surname><given-names>R.</given-names></name>
<name><surname>Weidle</surname><given-names>U.H.</given-names></name>
<name><surname>Piantelli</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Upregulation of Trop-2 Quantitatively Stimulates Human Cancer Growth</article-title><source>Oncogene</source><year>2013</year><volume>32</volume><fpage>222</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.36</pub-id><pub-id pub-id-type="pmid">22349828</pub-id>
</element-citation></ref><ref id="B72-pharmaceuticals-18-00262"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shvartsur</surname><given-names>A.</given-names></name>
<name><surname>Bonavida</surname><given-names>B.</given-names></name>
</person-group><article-title>Trop2 and Its Overexpression in Cancers: Regulation and Clinical/Therapeutic Implications</article-title><source>Genes Cancer</source><year>2015</year><volume>6</volume><fpage>84</fpage><pub-id pub-id-type="doi">10.18632/genesandcancer.40</pub-id><pub-id pub-id-type="pmid">26000093</pub-id>
</element-citation></ref><ref id="B73-pharmaceuticals-18-00262"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ambrogi</surname><given-names>F.</given-names></name>
<name><surname>Fornili</surname><given-names>M.</given-names></name>
<name><surname>Boracchi</surname><given-names>P.</given-names></name>
<name><surname>Trerotola</surname><given-names>M.</given-names></name>
<name><surname>Relli</surname><given-names>V.</given-names></name>
<name><surname>Simeone</surname><given-names>P.</given-names></name>
<name><surname>La Sorda</surname><given-names>R.</given-names></name>
<name><surname>Lattanzio</surname><given-names>R.</given-names></name>
<name><surname>Querzoli</surname><given-names>P.</given-names></name>
<name><surname>Pedriali</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Trop-2 Is a Determinant of Breast Cancer Survival</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e96993</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0096993</pub-id><pub-id pub-id-type="pmid">24824621</pub-id>
</element-citation></ref><ref id="B74-pharmaceuticals-18-00262"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>H.</given-names></name>
<name><surname>Huang</surname><given-names>J.-F.</given-names></name>
<name><surname>Qiu</surname><given-names>J.-R.</given-names></name>
<name><surname>Zhang</surname><given-names>H.-L.</given-names></name>
<name><surname>Tang</surname><given-names>X.-J.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>C.-J.</given-names></name>
<name><surname>Wang</surname><given-names>Z.-C.</given-names></name>
<name><surname>Feng</surname><given-names>Z.-Q.</given-names></name>
<name><surname>Zhu</surname><given-names>J.</given-names></name>
</person-group><article-title>Significantly Upregulated TACSTD2 and Cyclin D1 Correlate with Poor Prognosis of Invasive Ductal Breast Cancer</article-title><source>Exp. Mol. Pathol.</source><year>2013</year><volume>94</volume><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.yexmp.2012.08.004</pub-id><pub-id pub-id-type="pmid">23031786</pub-id>
</element-citation></ref><ref id="B75-pharmaceuticals-18-00262"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Chan</surname><given-names>C.</given-names></name>
</person-group><article-title>Identification of Novel Targets for Breast Cancer by Exploring Gene Switches on a Genome Scale</article-title><source>BMC Genom.</source><year>2011</year><volume>12</volume><elocation-id>547</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2164-12-547</pub-id></element-citation></ref><ref id="B76-pharmaceuticals-18-00262"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ning</surname><given-names>S.</given-names></name>
<name><surname>Liang</surname><given-names>N.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Pang</surname><given-names>Q.</given-names></name>
<name><surname>Xin</surname><given-names>T.</given-names></name>
</person-group><article-title>TROP2 Expression and Its Correlation with Tumor Proliferation and Angiogenesis in Human Gliomas</article-title><source>Neurol. Sci.</source><year>2013</year><volume>34</volume><fpage>1745</fpage><lpage>1750</lpage><pub-id pub-id-type="doi">10.1007/s10072-013-1326-8</pub-id><pub-id pub-id-type="pmid">23397225</pub-id>
</element-citation></ref><ref id="B77-pharmaceuticals-18-00262"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bardia</surname><given-names>A.</given-names></name>
<name><surname>Hurvitz</surname><given-names>S.A.</given-names></name>
<name><surname>Tolaney</surname><given-names>S.M.</given-names></name>
<name><surname>Loirat</surname><given-names>D.</given-names></name>
<name><surname>Punie</surname><given-names>K.</given-names></name>
<name><surname>Oliveira</surname><given-names>M.</given-names></name>
<name><surname>Brufsky</surname><given-names>A.</given-names></name>
<name><surname>Sardesai</surname><given-names>S.D.</given-names></name>
<name><surname>Kalinsky</surname><given-names>K.</given-names></name>
<name><surname>Zelnak</surname><given-names>A.B.</given-names></name>
<etal/>
</person-group><article-title>Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>384</volume><fpage>1529</fpage><lpage>1541</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2028485</pub-id><pub-id pub-id-type="pmid">33882206</pub-id>
</element-citation></ref><ref id="B78-pharmaceuticals-18-00262"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Balinda</surname><given-names>H.U.</given-names></name>
<name><surname>Kelly</surname><given-names>W.J.</given-names></name>
<name><surname>Kaklamani</surname><given-names>V.G.</given-names></name>
<name><surname>Lathrop</surname><given-names>K.I.</given-names></name>
<name><surname>Canola</surname><given-names>M.M.</given-names></name>
<name><surname>Ghamasaee</surname><given-names>P.</given-names></name>
<name><surname>Sareddy</surname><given-names>G.R.</given-names></name>
<name><surname>Michalek</surname><given-names>J.</given-names></name>
<name><surname>Gilbert</surname><given-names>A.R.</given-names></name>
<name><surname>Surapaneni</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Sacituzumab Govitecan in Patients with Breast Cancer Brain Metastases and Recurrent Glioblastoma: A Phase 0 Window-of-Opportunity Trial</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/s41467-024-50558-9</pub-id><pub-id pub-id-type="pmid">38169466</pub-id>
</element-citation></ref><ref id="B79-pharmaceuticals-18-00262"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suh</surname><given-names>W.-K.</given-names></name>
<name><surname>Tafuri</surname><given-names>A.</given-names></name>
<name><surname>Berg-Brown</surname><given-names>N.N.</given-names></name>
<name><surname>Shahinian</surname><given-names>A.</given-names></name>
<name><surname>Plyte</surname><given-names>S.</given-names></name>
<name><surname>Duncan</surname><given-names>G.S.</given-names></name>
<name><surname>Okada</surname><given-names>H.</given-names></name>
<name><surname>Wakeham</surname><given-names>A.</given-names></name>
<name><surname>Odermatt</surname><given-names>B.</given-names></name>
<name><surname>Ohashi</surname><given-names>P.S.</given-names></name>
<etal/>
</person-group><article-title>The Inducible Costimulator Plays the Major Costimulatory Role in Humoral Immune Responses in the Absence of CD28</article-title><source>J. Immunol.</source><year>2004</year><volume>172</volume><fpage>5917</fpage><lpage>5923</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.10.5917</pub-id><pub-id pub-id-type="pmid">15128772</pub-id>
</element-citation></ref><ref id="B80-pharmaceuticals-18-00262"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patsoukis</surname><given-names>N.</given-names></name>
<name><surname>Brown</surname><given-names>J.</given-names></name>
<name><surname>Petkova</surname><given-names>V.</given-names></name>
<name><surname>Liu</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Boussiotis</surname><given-names>V.A.</given-names></name>
</person-group><article-title>Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation</article-title><source>Sci. Signal.</source><year>2012</year><volume>5</volume><fpage>ra46</fpage><pub-id pub-id-type="doi">10.1126/scisignal.2002796</pub-id><pub-id pub-id-type="pmid">22740686</pub-id>
</element-citation></ref><ref id="B81-pharmaceuticals-18-00262"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Schwartz</surname><given-names>J.-C.D.</given-names></name>
<name><surname>Guo</surname><given-names>X.</given-names></name>
<name><surname>Bhatia</surname><given-names>S.</given-names></name>
<name><surname>Cao</surname><given-names>E.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.-Y.</given-names></name>
<name><surname>Edidin</surname><given-names>M.A.</given-names></name>
<name><surname>Nathenson</surname><given-names>S.G.</given-names></name>
<name><surname>Almo</surname><given-names>S.C.</given-names></name>
</person-group><article-title>Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1</article-title><source>Immunity</source><year>2004</year><volume>20</volume><fpage>337</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(04)00051-2</pub-id><pub-id pub-id-type="pmid">15030777</pub-id>
</element-citation></ref><ref id="B82-pharmaceuticals-18-00262"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hofmeyer</surname><given-names>K.A.</given-names></name>
<name><surname>Jeon</surname><given-names>H.</given-names></name>
<name><surname>Zang</surname><given-names>X.</given-names></name>
</person-group><article-title>The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion</article-title><source>BioMed Res. Int.</source><year>2011</year><volume>2011</volume><elocation-id>451694</elocation-id><pub-id pub-id-type="doi">10.1155/2011/451694</pub-id><pub-id pub-id-type="pmid">21960736</pub-id>
</element-citation></ref><ref id="B83-pharmaceuticals-18-00262"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Loi</surname><given-names>S.</given-names></name>
<name><surname>Drubay</surname><given-names>D.</given-names></name>
<name><surname>Adams</surname><given-names>S.</given-names></name>
<name><surname>Pruneri</surname><given-names>G.</given-names></name>
<name><surname>Francis</surname><given-names>P.A.</given-names></name>
<name><surname>Lacroix-Triki</surname><given-names>M.</given-names></name>
<name><surname>Joensuu</surname><given-names>H.</given-names></name>
<name><surname>Dieci</surname><given-names>M.V.</given-names></name>
<name><surname>Badve</surname><given-names>S.</given-names></name>
<name><surname>Demaria</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers</article-title><source>J. Clin. Oncol.</source><year>2019</year><volume>37</volume><fpage>559</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1200/JCO.18.01010</pub-id><pub-id pub-id-type="pmid">30650045</pub-id>
</element-citation></ref><ref id="B84-pharmaceuticals-18-00262"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kitano</surname><given-names>A.</given-names></name>
<name><surname>Ono</surname><given-names>M.</given-names></name>
<name><surname>Yoshida</surname><given-names>M.</given-names></name>
<name><surname>Noguchi</surname><given-names>E.</given-names></name>
<name><surname>Shimomura</surname><given-names>A.</given-names></name>
<name><surname>Shimoi</surname><given-names>T.</given-names></name>
<name><surname>Kodaira</surname><given-names>M.</given-names></name>
<name><surname>Yunokawa</surname><given-names>M.</given-names></name>
<name><surname>Yonemori</surname><given-names>K.</given-names></name>
<name><surname>Shimizu</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Tumour-Infiltrating Lymphocytes Are Correlated with Higher Expression Levels of PD-1 and PD-L1 in Early Breast Cancer</article-title><source>ESMO Open</source><year>2017</year><volume>2</volume><fpage>e000150</fpage><pub-id pub-id-type="doi">10.1136/esmoopen-2016-000150</pub-id><pub-id pub-id-type="pmid">28761741</pub-id>
</element-citation></ref><ref id="B85-pharmaceuticals-18-00262"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cortes</surname><given-names>J.</given-names></name>
<name><surname>Cescon</surname><given-names>D.W.</given-names></name>
<name><surname>Rugo</surname><given-names>H.S.</given-names></name>
<name><surname>Nowecki</surname><given-names>Z.</given-names></name>
<name><surname>Im</surname><given-names>S.-A.</given-names></name>
<name><surname>Yusof</surname><given-names>M.M.</given-names></name>
<name><surname>Gallardo</surname><given-names>C.</given-names></name>
<name><surname>Lipatov</surname><given-names>O.</given-names></name>
<name><surname>Barrios</surname><given-names>C.H.</given-names></name>
<name><surname>Holgado</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Pembrolizumab plus Chemotherapy versus Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (KEYNOTE-355): A Randomised, Placebo-Controlled, Double-Blind, Phase 3 Clinical Trial</article-title><source>Lancet</source><year>2020</year><volume>396</volume><fpage>1817</fpage><lpage>1828</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32531-9</pub-id><pub-id pub-id-type="pmid">33278935</pub-id>
</element-citation></ref><ref id="B86-pharmaceuticals-18-00262"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmid</surname><given-names>P.</given-names></name>
<name><surname>Cort&#x000e9;s</surname><given-names>J.</given-names></name>
<name><surname>Dent</surname><given-names>R.</given-names></name>
<name><surname>Pusztai</surname><given-names>L.</given-names></name>
<name><surname>McArthur</surname><given-names>H.L.</given-names></name>
<name><surname>Kuemmel</surname><given-names>S.</given-names></name>
<name><surname>Bergh</surname><given-names>J.</given-names></name>
<name><surname>Denkert</surname><given-names>C.</given-names></name>
<name><surname>Park</surname><given-names>Y.H.</given-names></name>
<name><surname>Hui</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>LBA8_PR&#x02014;KEYNOTE-522: Phase III Study of Pembrolizumab (Pembro) + Chemotherapy (Chemo) vs Placebo (Pbo) + Chemo as Neoadjuvant Treatment, Followed by Pembro vs Pbo as Adjuvant Treatment for Early Triple-Negative Breast Cancer (TNBC)</article-title><source>Ann. Oncol.</source><year>2019</year><volume>30</volume><fpage>v853</fpage><lpage>v854</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdz394.003</pub-id></element-citation></ref><ref id="B87-pharmaceuticals-18-00262"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmid</surname><given-names>P.</given-names></name>
<name><surname>Salgado</surname><given-names>R.</given-names></name>
<name><surname>Park</surname><given-names>Y.H.</given-names></name>
<name><surname>Mu&#x000f1;oz-Couselo</surname><given-names>E.</given-names></name>
<name><surname>Kim</surname><given-names>S.B.</given-names></name>
<name><surname>Sohn</surname><given-names>J.</given-names></name>
<name><surname>Im</surname><given-names>S.-A.</given-names></name>
<name><surname>Foukakis</surname><given-names>T.</given-names></name>
<name><surname>Kuemmel</surname><given-names>S.</given-names></name>
<name><surname>Dent</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Pembrolizumab plus Chemotherapy as Neoadjuvant Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: Results from the Phase 1b Open-Label, Multicohort KEYNOTE-173 Study</article-title><source>Ann. Oncol.</source><year>2020</year><volume>31</volume><fpage>569</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2020.01.072</pub-id><pub-id pub-id-type="pmid">32278621</pub-id>
</element-citation></ref><ref id="B88-pharmaceuticals-18-00262"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yokoi</surname><given-names>T.</given-names></name>
<name><surname>Oba</surname><given-names>T.</given-names></name>
<name><surname>Kajihara</surname><given-names>R.</given-names></name>
<name><surname>Abrams</surname><given-names>S.I.</given-names></name>
<name><surname>Ito</surname><given-names>F.</given-names></name>
</person-group><article-title>Local, Multimodal Intralesional Therapy Renders Distant Brain Metastases Susceptible to PD-L1 Blockade in a Preclinical Model of Triple-Negative Breast Cancer</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><elocation-id>21992</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-01455-4</pub-id><pub-id pub-id-type="pmid">34754037</pub-id>
</element-citation></ref><ref id="B89-pharmaceuticals-18-00262"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brastianos</surname><given-names>P.K.</given-names></name>
<name><surname>Kim</surname><given-names>A.E.</given-names></name>
<name><surname>Giobbie-Hurder</surname><given-names>A.</given-names></name>
<name><surname>Lee</surname><given-names>E.Q.</given-names></name>
<name><surname>Lin</surname><given-names>N.U.</given-names></name>
<name><surname>Overmoyer</surname><given-names>B.</given-names></name>
<name><surname>Wen</surname><given-names>P.Y.</given-names></name>
<name><surname>Nayak</surname><given-names>L.</given-names></name>
<name><surname>Cohen</surname><given-names>J.V.</given-names></name>
<name><surname>Dietrich</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Pembrolizumab in Brain Metastases of Diverse Histologies: Phase 2 Trial Results</article-title><source>Nat. Med.</source><year>2023</year><volume>29</volume><fpage>1728</fpage><lpage>1737</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02392-7</pub-id><pub-id pub-id-type="pmid">37268724</pub-id>
</element-citation></ref><ref id="B90-pharmaceuticals-18-00262"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giordano</surname><given-names>A.</given-names></name>
<name><surname>Kumthekar</surname><given-names>P.U.</given-names></name>
<name><surname>Jin</surname><given-names>Q.</given-names></name>
<name><surname>Binboga Kurt</surname><given-names>B.</given-names></name>
<name><surname>Ren</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Leone</surname><given-names>J.P.</given-names></name>
<name><surname>Mittendorf</surname><given-names>E.A.</given-names></name>
<name><surname>Pereslete</surname><given-names>A.M.</given-names></name>
<name><surname>Sharp</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer</article-title><source>Clin. Cancer Res.</source><year>2024</year><volume>30</volume><fpage>4856</fpage><lpage>4865</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-24-1161</pub-id><pub-id pub-id-type="pmid">39226397</pub-id>
</element-citation></ref><ref id="B91-pharmaceuticals-18-00262"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Winger</surname><given-names>R.C.</given-names></name>
<name><surname>Koblinski</surname><given-names>J.E.</given-names></name>
<name><surname>Kanda</surname><given-names>T.</given-names></name>
<name><surname>Ransohoff</surname><given-names>R.M.</given-names></name>
<name><surname>Muller</surname><given-names>W.A.</given-names></name>
</person-group><article-title>Rapid Remodeling of Tight Junctions during Paracellular Diapedesis in a Human Model of the Blood&#x02013;Brain Barrier</article-title><source>J. Immunol.</source><year>2014</year><volume>193</volume><fpage>2427</fpage><lpage>2437</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1400700</pub-id><pub-id pub-id-type="pmid">25063869</pub-id>
</element-citation></ref><ref id="B92-pharmaceuticals-18-00262"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Terstappen</surname><given-names>G.C.</given-names></name>
<name><surname>Meyer</surname><given-names>A.H.</given-names></name>
<name><surname>Bell</surname><given-names>R.D.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
</person-group><article-title>Strategies for Delivering Therapeutics across the Blood&#x02013;Brain Barrier</article-title><source>Nat. Rev. Drug Discov.</source><year>2021</year><volume>20</volume><fpage>362</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00139-y</pub-id><pub-id pub-id-type="pmid">33649582</pub-id>
</element-citation></ref><ref id="B93-pharmaceuticals-18-00262"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lajoie</surname><given-names>J.M.</given-names></name>
<name><surname>Shusta</surname><given-names>E.V.</given-names></name>
</person-group><article-title>Targeting Receptor-Mediated Transport for Delivery of Biologics across the Blood-Brain Barrier</article-title><source>Annu. Rev. Pharmacol. Toxicol.</source><year>2015</year><volume>55</volume><fpage>613</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010814-124852</pub-id><pub-id pub-id-type="pmid">25340933</pub-id>
</element-citation></ref><ref id="B94-pharmaceuticals-18-00262"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Liu</surname><given-names>Q.Y.</given-names></name>
<name><surname>Haqqani</surname><given-names>A.S.</given-names></name>
<name><surname>Leclerc</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Fauteux</surname><given-names>F.</given-names></name>
<name><surname>Baumann</surname><given-names>E.</given-names></name>
<name><surname>Delaney</surname><given-names>C.E.</given-names></name>
<name><surname>Ly</surname><given-names>D.</given-names></name>
<name><surname>Star</surname><given-names>A.T.</given-names></name>
<etal/>
</person-group><article-title>Differential Expression of Receptors Mediating Receptor-Mediated Transcytosis (RMT) in Brain Microvessels, Brain Parenchyma and Peripheral Tissues of the Mouse and the Human</article-title><source>Fluids Barriers CNS</source><year>2020</year><volume>17</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1186/s12987-020-00209-0</pub-id><pub-id pub-id-type="pmid">31931818</pub-id>
</element-citation></ref><ref id="B95-pharmaceuticals-18-00262"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumthekar</surname><given-names>P.</given-names></name>
<name><surname>Tang</surname><given-names>S.-C.</given-names></name>
<name><surname>Brenner</surname><given-names>A.J.</given-names></name>
<name><surname>Kesari</surname><given-names>S.</given-names></name>
<name><surname>Piccioni</surname><given-names>D.E.</given-names></name>
<name><surname>Anders</surname><given-names>C.</given-names></name>
<name><surname>Carrillo</surname><given-names>J.</given-names></name>
<name><surname>Chalasani</surname><given-names>P.</given-names></name>
<name><surname>Kabos</surname><given-names>P.</given-names></name>
<name><surname>Puhalla</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases</article-title><source>Clin. Cancer Res.</source><year>2020</year><volume>26</volume><fpage>2789</fpage><lpage>2799</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-3258</pub-id><pub-id pub-id-type="pmid">31969331</pub-id>
</element-citation></ref><ref id="B96-pharmaceuticals-18-00262"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>C.H.</given-names></name>
<name><surname>Zan</surname><given-names>B.</given-names></name>
<name><surname>Ulmschneider</surname><given-names>J.P.</given-names></name>
<name><surname>Wimley</surname><given-names>W.C.</given-names></name>
<name><surname>Lu</surname><given-names>T.K.</given-names></name>
<name><surname>Ulmschneider</surname><given-names>M.B.</given-names></name>
<name><surname>Zhou</surname><given-names>L.</given-names></name>
</person-group><article-title>Development of Membrane-active Peptide Therapeutics in Oncology</article-title><source>J. Pept. Sci.</source><year>2023</year><volume>29</volume><fpage>e3482</fpage><pub-id pub-id-type="doi">10.1002/psc.3482</pub-id><pub-id pub-id-type="pmid">36739581</pub-id>
</element-citation></ref><ref id="B97-pharmaceuticals-18-00262"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uceda-Castro</surname><given-names>R.</given-names></name>
<name><surname>Margarido</surname><given-names>A.S.</given-names></name>
<name><surname>Song</surname><given-names>J.-Y.</given-names></name>
<name><surname>de Gooijer</surname><given-names>M.C.</given-names></name>
<name><surname>Messal</surname><given-names>H.A.</given-names></name>
<name><surname>Chambers</surname><given-names>C.R.</given-names></name>
<name><surname>Nobis</surname><given-names>M.</given-names></name>
<name><surname>&#x000c7;itirikkaya</surname><given-names>C.H.</given-names></name>
<name><surname>Hahn</surname><given-names>K.</given-names></name>
<name><surname>Seinstra</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>BCRP Drives Intrinsic Chemoresistance in Chemotherapy-Na&#x000ef;ve Breast Cancer Brain Metastasis</article-title><source>Sci. Adv.</source><year>2023</year><volume>9</volume><fpage>eabp9530</fpage><pub-id pub-id-type="doi">10.1126/sciadv.abp9530</pub-id><pub-id pub-id-type="pmid">37851804</pub-id>
</element-citation></ref><ref id="B98-pharmaceuticals-18-00262"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Gooijer</surname><given-names>M.C.</given-names></name>
<name><surname>De Vries</surname><given-names>N.A.</given-names></name>
<name><surname>Buckle</surname><given-names>T.</given-names></name>
<name><surname>Buil</surname><given-names>L.C.M.</given-names></name>
<name><surname>Beijnen</surname><given-names>J.H.</given-names></name>
<name><surname>Boogerd</surname><given-names>W.</given-names></name>
<name><surname>Van Tellingen</surname><given-names>O.</given-names></name>
</person-group><article-title>Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2</article-title><source>Neoplasia</source><year>2018</year><volume>20</volume><fpage>710</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2018.05.001</pub-id><pub-id pub-id-type="pmid">29852323</pub-id>
</element-citation></ref><ref id="B99-pharmaceuticals-18-00262"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bailey-Dell</surname><given-names>K.J.</given-names></name>
<name><surname>Hassel</surname><given-names>B.</given-names></name>
<name><surname>Doyle</surname><given-names>L.A.</given-names></name>
<name><surname>Ross</surname><given-names>D.D.</given-names></name>
</person-group><article-title>Promoter Characterization and Genomic Organization of the Human Breast Cancer Resistance Protein (ATP-Binding Cassette Transporter G2) Gene1</article-title><source>Biochim. Biophys. Acta BBA Gene Struct. Expr.</source><year>2001</year><volume>1520</volume><fpage>234</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1016/S0167-4781(01)00270-6</pub-id><pub-id pub-id-type="pmid">11566359</pub-id>
</element-citation></ref><ref id="B100-pharmaceuticals-18-00262"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuang</surname><given-names>Y.-H.</given-names></name>
<name><surname>Shen</surname><given-names>T.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Sodani</surname><given-names>K.</given-names></name>
<name><surname>Hopper-Borge</surname><given-names>E.</given-names></name>
<name><surname>Tiwari</surname><given-names>A.K.</given-names></name>
<name><surname>Lee</surname><given-names>J.W.K.K.</given-names></name>
<name><surname>Fu</surname><given-names>L.-W.</given-names></name>
<name><surname>Chen</surname><given-names>Z.-S.</given-names></name>
</person-group><article-title>Lapatinib and Erlotinib Are Potent Reversal Agents for MRP7 (ABCC10)-Mediated Multidrug Resistance</article-title><source>Biochem. Pharmacol.</source><year>2010</year><volume>79</volume><fpage>154</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2009.08.021</pub-id><pub-id pub-id-type="pmid">19720054</pub-id>
</element-citation></ref><ref id="B101-pharmaceuticals-18-00262"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ambudkar</surname><given-names>S.V.</given-names></name>
<name><surname>Dey</surname><given-names>S.</given-names></name>
<name><surname>Hrycyna</surname><given-names>C.A.</given-names></name>
<name><surname>Ramachandra</surname><given-names>M.</given-names></name>
<name><surname>Pastan</surname><given-names>I.</given-names></name>
<name><surname>Gottesman</surname><given-names>M.M.</given-names></name>
</person-group><article-title>BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER1</article-title><source>Annu. Rev. Pharmacol. Toxicol.</source><year>1999</year><volume>39</volume><fpage>361</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.39.1.361</pub-id><pub-id pub-id-type="pmid">10331089</pub-id>
</element-citation></ref><ref id="B102-pharmaceuticals-18-00262"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeng</surname><given-names>W.</given-names></name>
<name><surname>Kwan Law</surname><given-names>B.Y.</given-names></name>
<name><surname>Wai Wong</surname><given-names>V.K.</given-names></name>
<name><surname>Bik Chan</surname><given-names>D.S.</given-names></name>
<name><surname>Fai Mok</surname><given-names>S.W.</given-names></name>
<name><surname>Ying Gao</surname><given-names>J.J.</given-names></name>
<name><surname>Yan Ho</surname><given-names>R.K.</given-names></name>
<name><surname>Liang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>J.H.</given-names></name>
<name><surname>Lee</surname><given-names>M.T.</given-names></name>
<etal/>
</person-group><article-title>HM30181A, a Potent P-Glycoprotein Inhibitor, Potentiates the Absorption and in Vivo Antitumor Efficacy of Paclitaxel in an Orthotopic Brain Tumor Model</article-title><source>Cancer Biol. Med.</source><year>2020</year><volume>17</volume><fpage>986</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.20892/j.issn.2095-3941.2020.0128</pub-id><pub-id pub-id-type="pmid">33299648</pub-id>
</element-citation></ref><ref id="B103-pharmaceuticals-18-00262"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rugo</surname><given-names>H.S.</given-names></name>
<name><surname>Umanzor</surname><given-names>G.A.</given-names></name>
<name><surname>Barrios</surname><given-names>F.J.</given-names></name>
<name><surname>Vasallo</surname><given-names>R.H.</given-names></name>
<name><surname>Chivalan</surname><given-names>M.A.</given-names></name>
<name><surname>Bejarano</surname><given-names>S.</given-names></name>
<name><surname>Ram&#x000ed;rez</surname><given-names>J.R.</given-names></name>
<name><surname>Fein</surname><given-names>L.</given-names></name>
<name><surname>Kowalyszyn</surname><given-names>R.D.</given-names></name>
<name><surname>Kramer</surname><given-names>E.D.</given-names></name>
<etal/>
</person-group><article-title>Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer</article-title><source>J. Clin. Oncol.</source><year>2023</year><volume>41</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1200/JCO.21.02953</pub-id><pub-id pub-id-type="pmid">35858154</pub-id>
</element-citation></ref><ref id="B104-pharmaceuticals-18-00262"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Christie</surname><given-names>E.L.</given-names></name>
<name><surname>Pattnaik</surname><given-names>S.</given-names></name>
<name><surname>Beach</surname><given-names>J.</given-names></name>
<name><surname>Copeland</surname><given-names>A.</given-names></name>
<name><surname>Rashoo</surname><given-names>N.</given-names></name>
<name><surname>Fereday</surname><given-names>S.</given-names></name>
<name><surname>Hendley</surname><given-names>J.</given-names></name>
<name><surname>Alsop</surname><given-names>K.</given-names></name>
<name><surname>Brady</surname><given-names>S.L.</given-names></name>
<name><surname>Lamb</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Multiple ABCB1 Transcriptional Fusions in Drug Resistant High-Grade Serous Ovarian and Breast Cancer</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>1295</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-09312-9</pub-id><pub-id pub-id-type="pmid">30894541</pub-id>
</element-citation></ref><ref id="B105-pharmaceuticals-18-00262"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yan</surname><given-names>M.</given-names></name>
<name><surname>Lv</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Cuizhi</surname><given-names>G.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Song</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Niu</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Feng</surname><given-names>Y.</given-names></name>
</person-group><article-title>Utidelone plus Bevacizumab for the Treatment of HER2-Negative Breast Cancer Brain Metastases (U-BOMB): A Multicenter, Single-Arm Phase II Study</article-title><source>JCO</source><year>2024</year><volume>42</volume><fpage>1081</fpage><pub-id pub-id-type="doi">10.1200/JCO.2024.42.16_suppl.1081</pub-id></element-citation></ref><ref id="B106-pharmaceuticals-18-00262"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>B.</given-names></name>
<name><surname>Sun</surname><given-names>T.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Yuan</surname><given-names>Z.</given-names></name>
<name><surname>Jiang</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Cui</surname><given-names>S.</given-names></name>
<name><surname>Teng</surname><given-names>Y.</given-names></name>
<name><surname>Hu</surname><given-names>X.-C.</given-names></name>
<etal/>
</person-group><article-title>Efficacy of Utidelone plus Capecitabine versus Capecitabine for Heavily Pretreated, Anthracycline- and Taxane-Refractory Metastatic Breast Cancer: Final Analysis of Overall Survival in a Phase III Randomised Controlled Trial</article-title><source>Ann. Oncol.</source><year>2021</year><volume>32</volume><fpage>218</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2020.10.600</pub-id><pub-id pub-id-type="pmid">33188874</pub-id>
</element-citation></ref><ref id="B107-pharmaceuticals-18-00262"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>L.S.</given-names></name>
<name><surname>Huang</surname><given-names>S.</given-names></name>
<name><surname>Lu</surname><given-names>W.</given-names></name>
<name><surname>Chelouche Lev</surname><given-names>D.</given-names></name>
<name><surname>Price</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Vascular Endothelial Growth Factor Expression Promotes the Growth of Breast Cancer Brain Metastases in Nude Mice</article-title><source>Clin. Exp. Metastasis</source><year>2004</year><volume>21</volume><fpage>107</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1023/B:CLIN.0000024761.00373.55</pub-id><pub-id pub-id-type="pmid">15168728</pub-id>
</element-citation></ref><ref id="B108-pharmaceuticals-18-00262"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>T.-H.</given-names></name>
<name><surname>Avraham</surname><given-names>H.K.</given-names></name>
<name><surname>Jiang</surname><given-names>S.</given-names></name>
<name><surname>Avraham</surname><given-names>S.</given-names></name>
</person-group><article-title>Vascular Endothelial Growth Factor Modulates the Transendothelial Migration of MDA-MB-231 Breast Cancer Cells through Regulation of Brain Microvascular Endothelial Cell Permeability*</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>5277</fpage><lpage>5284</lpage><pub-id pub-id-type="doi">10.1074/jbc.M210063200</pub-id><pub-id pub-id-type="pmid">12446667</pub-id>
</element-citation></ref><ref id="B109-pharmaceuticals-18-00262"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gray</surname><given-names>R.</given-names></name>
<name><surname>Bhattacharya</surname><given-names>S.</given-names></name>
<name><surname>Bowden</surname><given-names>C.</given-names></name>
<name><surname>Miller</surname><given-names>K.</given-names></name>
<name><surname>Comis</surname><given-names>R.L.</given-names></name>
</person-group><article-title>Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer</article-title><source>J. Clin. Oncol.</source><year>2009</year><volume>27</volume><fpage>4966</fpage><lpage>4972</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.21.6630</pub-id><pub-id pub-id-type="pmid">19720913</pub-id>
</element-citation></ref><ref id="B110-pharmaceuticals-18-00262"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miles</surname><given-names>D.W.</given-names></name>
<name><surname>Chan</surname><given-names>A.</given-names></name>
<name><surname>Dirix</surname><given-names>L.Y.</given-names></name>
<name><surname>Cort&#x000e9;s</surname><given-names>J.</given-names></name>
<name><surname>Pivot</surname><given-names>X.</given-names></name>
<name><surname>Tomczak</surname><given-names>P.</given-names></name>
<name><surname>Delozier</surname><given-names>T.</given-names></name>
<name><surname>Sohn</surname><given-names>J.H.</given-names></name>
<name><surname>Provencher</surname><given-names>L.</given-names></name>
<name><surname>Puglisi</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2&#x02013;Negative Metastatic Breast Cancer</article-title><source>JCO</source><year>2010</year><volume>28</volume><fpage>3239</fpage><lpage>3247</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.21.6457</pub-id></element-citation></ref><ref id="B111-pharmaceuticals-18-00262"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Robert</surname><given-names>N.J.</given-names></name>
<name><surname>Di&#x000e9;ras</surname><given-names>V.</given-names></name>
<name><surname>Glaspy</surname><given-names>J.</given-names></name>
<name><surname>Brufsky</surname><given-names>A.M.</given-names></name>
<name><surname>Bondarenko</surname><given-names>I.</given-names></name>
<name><surname>Lipatov</surname><given-names>O.N.</given-names></name>
<name><surname>Perez</surname><given-names>E.A.</given-names></name>
<name><surname>Yardley</surname><given-names>D.A.</given-names></name>
<name><surname>Chan</surname><given-names>S.Y.T.</given-names></name>
<name><surname>Zhou</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2&#x02013;Negative, Locally Recurrent or Metastatic Breast Cancer</article-title><source>JCO</source><year>2011</year><volume>29</volume><fpage>1252</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.28.0982</pub-id><pub-id pub-id-type="pmid">21383283</pub-id>
</element-citation></ref><ref id="B112-pharmaceuticals-18-00262"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leone</surname><given-names>J.P.</given-names></name>
<name><surname>Emblem</surname><given-names>K.E.</given-names></name>
<name><surname>Weitz</surname><given-names>M.</given-names></name>
<name><surname>Gelman</surname><given-names>R.S.</given-names></name>
<name><surname>Schneider</surname><given-names>B.P.</given-names></name>
<name><surname>Freedman</surname><given-names>R.A.</given-names></name>
<name><surname>Younger</surname><given-names>J.</given-names></name>
<name><surname>Pinho</surname><given-names>M.C.</given-names></name>
<name><surname>Sorensen</surname><given-names>A.G.</given-names></name>
<name><surname>Gerstner</surname><given-names>E.R.</given-names></name>
<etal/>
</person-group><article-title>Phase II Trial of Carboplatin and Bevacizumab in Patients with Breast Cancer Brain Metastases</article-title><source>Breast Cancer Res.</source><year>2020</year><volume>22</volume><fpage>131</fpage><pub-id pub-id-type="doi">10.1186/s13058-020-01372-w</pub-id><pub-id pub-id-type="pmid">33256829</pub-id>
</element-citation></ref><ref id="B113-pharmaceuticals-18-00262"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>T.W.-W.</given-names></name>
<name><surname>Dai</surname><given-names>M.-S.</given-names></name>
<name><surname>Tseng</surname><given-names>L.-M.</given-names></name>
<name><surname>Chen</surname><given-names>S.-C.</given-names></name>
<name><surname>Chao</surname><given-names>T.-Y.</given-names></name>
<name><surname>Chao</surname><given-names>T.-C.</given-names></name>
<name><surname>Chang</surname><given-names>Y.-C.</given-names></name>
<name><surname>Chiu</surname><given-names>C.-F.</given-names></name>
<name><surname>Liu</surname><given-names>C.-T.</given-names></name>
<name><surname>Lin</surname><given-names>C.-H.</given-names></name>
<etal/>
</person-group><article-title>Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial</article-title><source>JAMA Oncol.</source><year>2024</year><volume>10</volume><fpage>325</fpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2023.5456</pub-id><pub-id pub-id-type="pmid">38127335</pub-id>
</element-citation></ref><ref id="B114-pharmaceuticals-18-00262"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wangensteen</surname><given-names>S.M.</given-names></name>
<name><surname>Sayyad</surname><given-names>M.</given-names></name>
<name><surname>Puchalapalli</surname><given-names>M.</given-names></name>
<name><surname>Sullivan</surname><given-names>M.</given-names></name>
<name><surname>Singh</surname><given-names>J.</given-names></name>
<name><surname>Ratchford</surname><given-names>B.</given-names></name>
<name><surname>Abrams</surname><given-names>J.</given-names></name>
<name><surname>Jahromi</surname><given-names>M.</given-names></name>
<name><surname>Hu</surname><given-names>B.</given-names></name>
<name><surname>Idowu</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Abstract 3058: Syndecan-1 Mediates Breast Cancer Metastasis to the Brain through IL-8 and PECAM-1 Signaling</article-title><source>Cancer Res.</source><year>2017</year><volume>77</volume><fpage>3058</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2017-3058</pub-id></element-citation></ref><ref id="B115-pharmaceuticals-18-00262"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benchama</surname><given-names>O.</given-names></name>
<name><surname>Tyukhtenko</surname><given-names>S.</given-names></name>
<name><surname>Malamas</surname><given-names>M.S.</given-names></name>
<name><surname>Williams</surname><given-names>M.K.</given-names></name>
<name><surname>Makriyannis</surname><given-names>A.</given-names></name>
<name><surname>Avraham</surname><given-names>H.K.</given-names></name>
</person-group><article-title>Inhibition of Triple Negative Breast Cancer-Associated Inflammation, Tumor Growth and Brain Colonization by Targeting Monoacylglycerol Lipase</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><elocation-id>5328</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-09358-8</pub-id><pub-id pub-id-type="pmid">35351947</pub-id>
</element-citation></ref><ref id="B116-pharmaceuticals-18-00262"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sabel</surname><given-names>M.</given-names></name>
<name><surname>Rommel</surname><given-names>F.</given-names></name>
<name><surname>Kondakci</surname><given-names>M.</given-names></name>
<name><surname>Gorol</surname><given-names>M.</given-names></name>
<name><surname>Willers</surname><given-names>R.</given-names></name>
<name><surname>Bilzer</surname><given-names>T.</given-names></name>
</person-group><article-title>Locoregional Opening of the Rodent Blood&#x02013;Brain Barrier for Paclitaxel Using Nd:YAG Laser-Induced Thermo Therapy: A New Concept of Adjuvant Glioma Therapy?</article-title><source>Lasers Surg. Med.</source><year>2003</year><volume>33</volume><fpage>75</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1002/lsm.10181</pub-id><pub-id pub-id-type="pmid">12913878</pub-id>
</element-citation></ref><ref id="B117-pharmaceuticals-18-00262"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shang</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Xue</surname><given-names>Y.</given-names></name>
</person-group><article-title>Mechanism of Low-Frequency Ultrasound in Opening Blood-Tumor Barrier by Tight Junction</article-title><source>J. Mol. Neurosci.</source><year>2011</year><volume>43</volume><fpage>364</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1007/s12031-010-9451-9</pub-id><pub-id pub-id-type="pmid">20852968</pub-id>
</element-citation></ref><ref id="B118-pharmaceuticals-18-00262"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alli</surname><given-names>S.</given-names></name>
<name><surname>Figueiredo</surname><given-names>C.A.</given-names></name>
<name><surname>Golbourn</surname><given-names>B.</given-names></name>
<name><surname>Sabha</surname><given-names>N.</given-names></name>
<name><surname>Wu</surname><given-names>M.Y.</given-names></name>
<name><surname>Bondoc</surname><given-names>A.</given-names></name>
<name><surname>Luck</surname><given-names>A.</given-names></name>
<name><surname>Coluccia</surname><given-names>D.</given-names></name>
<name><surname>Maslink</surname><given-names>C.</given-names></name>
<name><surname>Smith</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Brainstem Blood Brain Barrier Disruption Using Focused Ultrasound: A Demonstration of Feasibility and Enhanced Doxorubicin Delivery</article-title><source>J. Control. Release</source><year>2018</year><volume>281</volume><fpage>29</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2018.05.005</pub-id><pub-id pub-id-type="pmid">29753957</pub-id>
</element-citation></ref><ref id="B119-pharmaceuticals-18-00262"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>E.-J.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.-Z.</given-names></name>
<name><surname>Vykhodtseva</surname><given-names>N.</given-names></name>
<name><surname>McDannold</surname><given-names>N.</given-names></name>
</person-group><article-title>Ultrasound-Mediated Blood-brain/Blood-Tumor Barrier Disruption Improves Outcomes with Trastuzumab in a Breast Cancer Brain Metastasis Model</article-title><source>J. Control. Release</source><year>2012</year><volume>163</volume><fpage>277</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2012.09.007</pub-id><pub-id pub-id-type="pmid">23000189</pub-id>
</element-citation></ref><ref id="B120-pharmaceuticals-18-00262"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>W.</given-names></name>
<name><surname>Fan</surname><given-names>W.</given-names></name>
<name><surname>Lau</surname><given-names>J.</given-names></name>
<name><surname>Deng</surname><given-names>L.</given-names></name>
<name><surname>Shen</surname><given-names>Z.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
</person-group><article-title>Emerging Blood&#x02013;Brain-Barrier-Crossing Nanotechnology for Brain Cancer Theranostics</article-title><source>Chem. Soc. Rev.</source><year>2019</year><volume>48</volume><fpage>2967</fpage><lpage>3014</lpage><pub-id pub-id-type="doi">10.1039/C8CS00805A</pub-id><pub-id pub-id-type="pmid">31089607</pub-id>
</element-citation></ref><ref id="B121-pharmaceuticals-18-00262"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ansari</surname><given-names>M.A.</given-names></name>
<name><surname>Thiruvengadam</surname><given-names>M.</given-names></name>
<name><surname>Farooqui</surname><given-names>Z.</given-names></name>
<name><surname>Rajakumar</surname><given-names>G.</given-names></name>
<name><surname>Sajid Jamal</surname><given-names>Q.M.</given-names></name>
<name><surname>Alzohairy</surname><given-names>M.A.</given-names></name>
<name><surname>Almatroudi</surname><given-names>A.</given-names></name>
<name><surname>Alomary</surname><given-names>M.N.</given-names></name>
<name><surname>Chung</surname><given-names>I.-M.</given-names></name>
<name><surname>Al-Suhaimi</surname><given-names>E.A.</given-names></name>
</person-group><article-title>Nanotechnology, in Silico and Endocrine-Based Strategy for Delivering Paclitaxel and miRNA: Prospects for the Therapeutic Management of Breast Cancer</article-title><source>Semin. Cancer Biol.</source><year>2021</year><volume>69</volume><fpage>109</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2019.12.022</pub-id><pub-id pub-id-type="pmid">31891780</pub-id>
</element-citation></ref><ref id="B122-pharmaceuticals-18-00262"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pe&#x000f1;a</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>A.</given-names></name>
<name><surname>Zaremba</surname><given-names>O.</given-names></name>
<name><surname>Shi</surname><given-names>Y.</given-names></name>
<name><surname>Scheeren</surname><given-names>H.W.</given-names></name>
<name><surname>Metselaar</surname><given-names>J.M.</given-names></name>
<name><surname>Kiessling</surname><given-names>F.</given-names></name>
<name><surname>Pallares</surname><given-names>R.M.</given-names></name>
<name><surname>Wuttke</surname><given-names>S.</given-names></name>
<name><surname>Lammers</surname><given-names>T.</given-names></name>
</person-group><article-title>Metallodrugs in Cancer Nanomedicine</article-title><source>Chem. Soc. Rev.</source><year>2022</year><volume>51</volume><fpage>2544</fpage><lpage>2582</lpage><pub-id pub-id-type="doi">10.1039/D1CS00468A</pub-id><pub-id pub-id-type="pmid">35262108</pub-id>
</element-citation></ref><ref id="B123-pharmaceuticals-18-00262"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>C.</given-names></name>
<name><surname>Cai</surname><given-names>P.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>T.</given-names></name>
<name><surname>Lin</surname><given-names>L.</given-names></name>
<name><surname>Abbasi</surname><given-names>A.Z.</given-names></name>
<name><surname>Henderson</surname><given-names>J.T.</given-names></name>
<name><surname>Rauth</surname><given-names>A.M.</given-names></name>
<name><surname>Wu</surname><given-names>X.Y.</given-names></name>
</person-group><article-title>Blood-Brain Barrier-Penetrating Amphiphilic Polymer Nanoparticles Deliver Docetaxel for the Treatment of Brain Metastases of Triple Negative Breast Cancer</article-title><source>J. Control. Release</source><year>2017</year><volume>246</volume><fpage>98</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2016.12.019</pub-id><pub-id pub-id-type="pmid">28017889</pub-id>
</element-citation></ref><ref id="B124-pharmaceuticals-18-00262"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohammad</surname><given-names>A.S.</given-names></name>
<name><surname>Griffith</surname><given-names>J.I.</given-names></name>
<name><surname>Adkins</surname><given-names>C.E.</given-names></name>
<name><surname>Shah</surname><given-names>N.</given-names></name>
<name><surname>Sechrest</surname><given-names>E.</given-names></name>
<name><surname>Dolan</surname><given-names>E.L.</given-names></name>
<name><surname>Terrell-Hall</surname><given-names>T.B.</given-names></name>
<name><surname>Hendriks</surname><given-names>B.S.</given-names></name>
<name><surname>Lee</surname><given-names>H.</given-names></name>
<name><surname>Lockman</surname><given-names>P.R.</given-names></name>
</person-group><article-title>Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer</article-title><source>Pharm. Res.</source><year>2018</year><volume>35</volume><fpage>31</fpage><pub-id pub-id-type="doi">10.1007/s11095-017-2278-0</pub-id><pub-id pub-id-type="pmid">29368289</pub-id>
</element-citation></ref><ref id="B125-pharmaceuticals-18-00262"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sachdev</surname><given-names>J.C.</given-names></name>
<name><surname>Munster</surname><given-names>P.</given-names></name>
<name><surname>Northfelt</surname><given-names>D.W.</given-names></name>
<name><surname>Han</surname><given-names>H.S.</given-names></name>
<name><surname>Ma</surname><given-names>C.</given-names></name>
<name><surname>Maxwell</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Belanger</surname><given-names>B.</given-names></name>
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Moore</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Phase I Study of Liposomal Irinotecan in Patients with Metastatic Breast Cancer: Findings from the Expansion Phase</article-title><source>Breast Cancer Res. Treat.</source><year>2021</year><volume>185</volume><fpage>759</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1007/s10549-020-05995-7</pub-id><pub-id pub-id-type="pmid">33201358</pub-id>
</element-citation></ref><ref id="B126-pharmaceuticals-18-00262"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>T.</given-names></name>
<name><surname>Lip</surname><given-names>H.</given-names></name>
<name><surname>He</surname><given-names>C.</given-names></name>
<name><surname>Cai</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Henderson</surname><given-names>J.T.</given-names></name>
<name><surname>Rauth</surname><given-names>A.M.</given-names></name>
<name><surname>Wu</surname><given-names>X.Y.</given-names></name>
</person-group><article-title>Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood&#x02013;Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages</article-title><source>Adv. Healthc. Mater.</source><year>2019</year><volume>8</volume><fpage>1900543</fpage><pub-id pub-id-type="doi">10.1002/adhm.201900543</pub-id><pub-id pub-id-type="pmid">31348614</pub-id>
</element-citation></ref><ref id="B127-pharmaceuticals-18-00262"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Xie</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>K.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Yin</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Lu</surname><given-names>G.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Wei</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Gold Nanoparticle-Directed Autophagy Intervention for Antitumor Immunotherapy via Inhibiting Tumor-Associated Macrophage M2 Polarization</article-title><source>Acta Pharm. Sin. B</source><year>2022</year><volume>12</volume><fpage>3124</fpage><lpage>3138</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2022.02.008</pub-id><pub-id pub-id-type="pmid">35865102</pub-id>
</element-citation></ref><ref id="B128-pharmaceuticals-18-00262"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiang</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Lu</surname><given-names>D.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
</person-group><article-title>Targeting Tumor-Associated Macrophages to Synergize Tumor Immunotherapy</article-title><source>Signal Transduct Target Ther.</source><year>2021</year><volume>6</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/s41392-021-00484-9</pub-id><pub-id pub-id-type="pmid">33384407</pub-id>
</element-citation></ref><ref id="B129-pharmaceuticals-18-00262"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Qu</surname><given-names>J.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Ma</surname><given-names>X.</given-names></name>
<name><surname>Gao</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Prognostic Significance of Tumor-Associated Macrophages in Breast Cancer: A Meta-Analysis of the Literature</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>30576</fpage><lpage>30586</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.15736</pub-id><pub-id pub-id-type="pmid">28427165</pub-id>
</element-citation></ref><ref id="B130-pharmaceuticals-18-00262"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zanganeh</surname><given-names>S.</given-names></name>
<name><surname>Hutter</surname><given-names>G.</given-names></name>
<name><surname>Spitler</surname><given-names>R.</given-names></name>
<name><surname>Lenkov</surname><given-names>O.</given-names></name>
<name><surname>Mahmoudi</surname><given-names>M.</given-names></name>
<name><surname>Shaw</surname><given-names>A.</given-names></name>
<name><surname>Pajarinen</surname><given-names>J.S.</given-names></name>
<name><surname>Nejadnik</surname><given-names>H.</given-names></name>
<name><surname>Goodman</surname><given-names>S.</given-names></name>
<name><surname>Moseley</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Iron Oxide Nanoparticles Inhibit Tumour Growth by Inducing Pro-Inflammatory Macrophage Polarization in Tumour Tissues</article-title><source>Nat. Nanotechnol.</source><year>2016</year><volume>11</volume><fpage>986</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1038/nnano.2016.168</pub-id><pub-id pub-id-type="pmid">27668795</pub-id>
</element-citation></ref><ref id="B131-pharmaceuticals-18-00262"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tong</surname><given-names>F.</given-names></name>
<name><surname>Hu</surname><given-names>H.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Xie</surname><given-names>R.</given-names></name>
<name><surname>Lei</surname><given-names>T.</given-names></name>
<name><surname>Du</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>W.</given-names></name>
<name><surname>He</surname><given-names>S.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Hollow Copper Sulfide Nanoparticles Carrying ISRIB for the Sensitized Photothermal Therapy of Breast Cancer and Brain Metastases through Inhibiting Stress Granule Formation and Reprogramming Tumor-associated Macrophages</article-title><source>Acta Pharm. Sin. B</source><year>2023</year><volume>13</volume><fpage>3471</fpage><lpage>3488</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2022.11.003</pub-id><pub-id pub-id-type="pmid">37655313</pub-id>
</element-citation></ref><ref id="B132-pharmaceuticals-18-00262"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rao</surname><given-names>L.</given-names></name>
<name><surname>Zhao</surname><given-names>S.-K.</given-names></name>
<name><surname>Wen</surname><given-names>C.</given-names></name>
<name><surname>Tian</surname><given-names>R.</given-names></name>
<name><surname>Lin</surname><given-names>L.</given-names></name>
<name><surname>Cai</surname><given-names>B.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Kang</surname><given-names>F.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>He</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Activating Macrophage-Mediated Cancer Immunotherapy by Genetically Edited Nanoparticles</article-title><source>Adv. Mater.</source><year>2020</year><volume>32</volume><fpage>e2004853</fpage><pub-id pub-id-type="doi">10.1002/adma.202004853</pub-id><pub-id pub-id-type="pmid">33089578</pub-id>
</element-citation></ref><ref id="B133-pharmaceuticals-18-00262"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ashrafizadeh</surname><given-names>M.</given-names></name>
<name><surname>Zarrabi</surname><given-names>A.</given-names></name>
<name><surname>Bigham</surname><given-names>A.</given-names></name>
<name><surname>Taheriazam</surname><given-names>A.</given-names></name>
<name><surname>Saghari</surname><given-names>Y.</given-names></name>
<name><surname>Mirzaei</surname><given-names>S.</given-names></name>
<name><surname>Hashemi</surname><given-names>M.</given-names></name>
<name><surname>Hushmandi</surname><given-names>K.</given-names></name>
<name><surname>Karimi-Maleh</surname><given-names>H.</given-names></name>
<name><surname>Nazarzadeh Zare</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>(Nano)Platforms in Breast Cancer Therapy: Drug/Gene Delivery, Advanced Nanocarriers and Immunotherapy</article-title><source>Med. Res. Rev.</source><year>2023</year><volume>43</volume><fpage>2115</fpage><lpage>2176</lpage><pub-id pub-id-type="doi">10.1002/med.21971</pub-id><pub-id pub-id-type="pmid">37165896</pub-id>
</element-citation></ref><ref id="B134-pharmaceuticals-18-00262"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Subhan</surname><given-names>M.A.</given-names></name>
<name><surname>Muzibur Rahman</surname><given-names>M.</given-names></name>
</person-group><article-title>Recent Development in Metallic Nanoparticles for Breast Cancer Therapy and Diagnosis</article-title><source>Chem. Rec.</source><year>2022</year><volume>22</volume><fpage>e202100331</fpage><pub-id pub-id-type="doi">10.1002/tcr.202100331</pub-id><pub-id pub-id-type="pmid">35146897</pub-id>
</element-citation></ref><ref id="B135-pharmaceuticals-18-00262"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Stevens</surname><given-names>M.F.G.</given-names></name>
<name><surname>Bradshaw</surname><given-names>T.D.</given-names></name>
</person-group><article-title>Temozolomide: Mechanisms of Action, Repair and Resistance</article-title><source>Curr. Mol. Pharmacol.</source><year>2012</year><volume>5</volume><fpage>102</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.2174/1874467211205010102</pub-id><pub-id pub-id-type="pmid">22122467</pub-id>
</element-citation></ref><ref id="B136-pharmaceuticals-18-00262"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trudeau</surname><given-names>M.E.</given-names></name>
<name><surname>Crump</surname><given-names>M.</given-names></name>
<name><surname>Charpentier</surname><given-names>D.</given-names></name>
<name><surname>Yelle</surname><given-names>L.</given-names></name>
<name><surname>Bordeleau</surname><given-names>L.</given-names></name>
<name><surname>Matthews</surname><given-names>S.</given-names></name>
<name><surname>Eisenhauer</surname><given-names>E.</given-names></name>
</person-group><article-title>Temozolomide in Metastatic Breast Cancer (MBC): A Phase II Trial of the National Cancer Institute of Canada&#x02014;Clinical Trials Group (NCIC-CTG)</article-title><source>Ann. Oncol.</source><year>2006</year><volume>17</volume><fpage>952</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdl056</pub-id><pub-id pub-id-type="pmid">16565212</pub-id>
</element-citation></ref><ref id="B137-pharmaceuticals-18-00262"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shao</surname><given-names>Z.</given-names></name>
<name><surname>Pang</surname><given-names>D.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Cui</surname><given-names>S.</given-names></name>
<name><surname>Liao</surname><given-names>N.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Chang</surname><given-names>Y.-C.</given-names></name>
<etal/>
</person-group><article-title>Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial</article-title><source>JAMA Oncol.</source><year>2020</year><volume>6</volume><fpage>e193692</fpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2019.3692</pub-id><pub-id pub-id-type="pmid">31647503</pub-id>
</element-citation></ref><ref id="B138-pharmaceuticals-18-00262"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>D.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Ma</surname><given-names>F.</given-names></name>
</person-group><article-title>Efficacy and Safety of Trastuzumab with or Without a Tyrosine Kinase Inhibitor for HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis</article-title><source>Biochim. Biophys. Acta BBA Rev. Cancer</source><year>2023</year><volume>1878</volume><elocation-id>188969</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbcan.2023.188969</pub-id></element-citation></ref><ref id="B139-pharmaceuticals-18-00262"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klocker</surname><given-names>E.V.</given-names></name>
<name><surname>Egle</surname><given-names>D.</given-names></name>
<name><surname>Bartsch</surname><given-names>R.</given-names></name>
<name><surname>Rinnerthaler</surname><given-names>G.</given-names></name>
<name><surname>Gnant</surname><given-names>M.</given-names></name>
</person-group><article-title>Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2- Early Breast Cancer</article-title><source>Drugs</source><year>2025</year><volume>85</volume><fpage>149</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1007/s40265-024-02144-y</pub-id><pub-id pub-id-type="pmid">39820840</pub-id>
</element-citation></ref><ref id="B140-pharmaceuticals-18-00262"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bardia</surname><given-names>A.</given-names></name>
<name><surname>Mayer</surname><given-names>I.A.</given-names></name>
<name><surname>Diamond</surname><given-names>J.R.</given-names></name>
<name><surname>Moroose</surname><given-names>R.L.</given-names></name>
<name><surname>Isakoff</surname><given-names>S.J.</given-names></name>
<name><surname>Starodub</surname><given-names>A.N.</given-names></name>
<name><surname>Shah</surname><given-names>N.C.</given-names></name>
<name><surname>O&#x02019;Shaughnessy</surname><given-names>J.</given-names></name>
<name><surname>Kalinsky</surname><given-names>K.</given-names></name>
<name><surname>Guarino</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer</article-title><source>J. Clin. Oncol.</source><year>2017</year><volume>35</volume><fpage>2141</fpage><lpage>2148</lpage><pub-id pub-id-type="doi">10.1200/JCO.2016.70.8297</pub-id><pub-id pub-id-type="pmid">28291390</pub-id>
</element-citation></ref><ref id="B141-pharmaceuticals-18-00262"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kong</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Su</surname><given-names>Z.</given-names></name>
<name><surname>Sullivan</surname><given-names>R.J.</given-names></name>
<name><surname>Blum</surname><given-names>S.M.</given-names></name>
<name><surname>Qi</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Huo</surname><given-names>Y.</given-names></name>
<name><surname>Fang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Toxicities Associated with Immune Checkpoint Inhibitors: A Systematic Study</article-title><source>Int. J. Surg.</source><year>2023</year><volume>109</volume><fpage>1753</fpage><lpage>1768</lpage><pub-id pub-id-type="doi">10.1097/JS9.0000000000000368</pub-id><pub-id pub-id-type="pmid">37132038</pub-id>
</element-citation></ref><ref id="B142-pharmaceuticals-18-00262"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brastianos</surname><given-names>P.K.</given-names></name>
<name><surname>Carter</surname><given-names>S.L.</given-names></name>
<name><surname>Santagata</surname><given-names>S.</given-names></name>
<name><surname>Cahill</surname><given-names>D.P.</given-names></name>
<name><surname>Taylor-Weiner</surname><given-names>A.</given-names></name>
<name><surname>Jones</surname><given-names>R.T.</given-names></name>
<name><surname>Van Allen</surname><given-names>E.M.</given-names></name>
<name><surname>Lawrence</surname><given-names>M.S.</given-names></name>
<name><surname>Horowitz</surname><given-names>P.M.</given-names></name>
<name><surname>Cibulskis</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets</article-title><source>Cancer Discov.</source><year>2015</year><volume>5</volume><fpage>1164</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0369</pub-id><pub-id pub-id-type="pmid">26410082</pub-id>
</element-citation></ref><ref id="B143-pharmaceuticals-18-00262"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yates</surname><given-names>L.R.</given-names></name>
<name><surname>Knappskog</surname><given-names>S.</given-names></name>
<name><surname>Wedge</surname><given-names>D.</given-names></name>
<name><surname>Farmery</surname><given-names>J.H.R.</given-names></name>
<name><surname>Gonzalez</surname><given-names>S.</given-names></name>
<name><surname>Martincorena</surname><given-names>I.</given-names></name>
<name><surname>Alexandrov</surname><given-names>L.B.</given-names></name>
<name><surname>Loo</surname><given-names>P.V.</given-names></name>
<name><surname>Haugland</surname><given-names>H.K.</given-names></name>
<name><surname>Lilleng</surname><given-names>P.K.</given-names></name>
<etal/>
</person-group><article-title>Genomic Evolution of Breast Cancer Metastasis and Relapse</article-title><source>Cancer Cell</source><year>2017</year><volume>32</volume><fpage>169</fpage><lpage>184.e7</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.07.005</pub-id><pub-id pub-id-type="pmid">28810143</pub-id>
</element-citation></ref><ref id="B144-pharmaceuticals-18-00262"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mattos-Arruda</surname><given-names>L.D.</given-names></name>
</person-group><article-title>Liquid Biopsy for HER2-Positive Breast Cancer Brain Metastasis: The Role of the Cerebrospinal Fluid</article-title><source>ESMO Open</source><year>2017</year><volume>2</volume><fpage>e000270</fpage><pub-id pub-id-type="doi">10.1136/esmoopen-2017-000270</pub-id><pub-id pub-id-type="pmid">29067217</pub-id>
</element-citation></ref><ref id="B145-pharmaceuticals-18-00262"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Waks</surname><given-names>A.G.</given-names></name>
<name><surname>Winer</surname><given-names>E.P.</given-names></name>
</person-group><article-title>Breast Cancer Treatment: A Review</article-title><source>JAMA</source><year>2019</year><volume>321</volume><fpage>288</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1001/jama.2018.19323</pub-id><pub-id pub-id-type="pmid">30667505</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceuticals-18-00262-f001"><label>Figure 1</label><caption><p>Breast cancer cells metastasize to the brain. Breast cancer cells undergo epithelial-mesenchymal transition (EMT) to become invasive. The invasive cancer cells then enter the circulatory system and become circulating tumor cells (CTCs) with the help of macrophages and endothelial cells (ECs). CTCs spread through the bloodstream to the brain, where they migrate transendothelially (TEM) by rolling, adhering to, and finally crossing the blood-brain barrier (BBB), a specialized structure made up of endothelial cells (ECs), pericytes, basement membranes, and astrocytes. Tight junctions (TJ) between endothelial cells limit paracellular transport to the brain. However, CTC induces disruption of the TJ, enhances BBB permeability, and facilitates CTC extravasation to the brain. Pericytes can also maintain BBB function by regulating TJ formation in the EC and by secreting components of the endothelial basement membrane.</p></caption><graphic xlink:href="pharmaceuticals-18-00262-g001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00262-f002"><label>Figure 2</label><caption><p>Mechanism of action of anti-HER2 drugs. The HER family includes HER1, HER2, HER3 and HER4, among which HER2 overexpression is the most common in breast cancer patients. HER is a typical cell membrane receptor tyrosine kinase, and due to HER2 overexpression, heterodimerization of this receptor with other members of the EGFR family leads to autophosphorylation of tyrosine residues within the cytoplasmic domain of heterodimeric and initiation of Akt, MAPK, and various other signaling pathways leading to cell proliferation and tumorigenesis [<xref rid="B24-pharmaceuticals-18-00262" ref-type="bibr">24</xref>]. As early as the 90s of the last century, the anti-HER2 monoclonal antibody trastuzumab has achieved good clinical efficacy [<xref rid="B25-pharmaceuticals-18-00262" ref-type="bibr">25</xref>], and then the new monoclonal antibody Pertuzumab inhibits the MAPK and PI3K signaling pathways by inhibiting HER2 dimerization and inhibiting the growth and development of tumor cells [<xref rid="B26-pharmaceuticals-18-00262" ref-type="bibr">26</xref>]. With the development of antibody-drug conjugates, HER2 antibody conjugates T-DM1 and T-DXd have also achieved good efficacy, both of which enhance the killing effect on tumor cells by attaching small molecule toxin drugs to HER2 monoclonal antibodies and then transporting the toxin drug into the cell [<xref rid="B27-pharmaceuticals-18-00262" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceuticals-18-00262" ref-type="bibr">28</xref>]. Lapatinib, pyrotinib, and tucatinib, as TKIs, can also inhibit tumor development by inhibiting the MAPK signaling pathway [<xref rid="B29-pharmaceuticals-18-00262" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceuticals-18-00262" ref-type="bibr">30</xref>].</p></caption><graphic xlink:href="pharmaceuticals-18-00262-g002" position="float"/></fig><table-wrap position="float" id="pharmaceuticals-18-00262-t001"><object-id pub-id-type="pii">pharmaceuticals-18-00262-t001_Table 1</object-id><label>Table 1</label><caption><p>Major clinical trials of HER2-targeting drugs in patients with metastatic breast cancer. &#x0201c;---&#x0201d; indicates that this information is not mentioned in the experiment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Classification</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Research Title</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Design</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ORR</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">OS</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PFS</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Monoclonal antibodies</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Pertuzumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PATRICIA [<xref rid="B31-pharmaceuticals-18-00262" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pertuzumab plus high-dose trastuzumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical benefit rates at 4 months and 6 months were 68% and 51%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">---</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">---</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CLEOPATRA [<xref rid="B32-pharmaceuticals-18-00262" ref-type="bibr">32</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pertuzumab, trastuzumab, and docetaxel vs. placebo, trastuzumab, and docetaxel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">---</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57.1 months(Pertuzumab) vs. 40.8 months(placebo)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53.8 months(pertuzumab) vs. 46.6 months(placebo)</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">TKI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lapatinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ELTOP [<xref rid="B33-pharmaceuticals-18-00262" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lapatinib plus capecitabine vs. trastuzumab plus capecitabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41% (lapatinib plus capecitabine) vs. 40% (trastuzumab plus capecitabine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">--- vs. 6.1 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.1 months (lapatinib plus capecitabine)<break/>vs. 6.1 months (trastuzumab plus capecitabine)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neratinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TBCRC 022 [<xref rid="B34-pharmaceuticals-18-00262" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lapatinib-na&#x000ef;ve vs. lapatinib-treated added to neratinib, capecitabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49% (lapatinib-na&#x000ef;ve) vs. 33% (lapatinib-treated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.3 months (lapatinib-na&#x000ef;ve) vs. 15.1 months (lapatinib-treated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.5 months (lapatinib-na&#x000ef;ve) vs. 3.1 months (lapatinib-treated)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pyrotinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PERMEATE [<xref rid="B35-pharmaceuticals-18-00262" ref-type="bibr">35</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No radiotherapy vs. radiotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">---</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.0 months vs. 31.5 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.3 months (No radiotherapy) vs. 5.6 months (radiotherapy)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tucatinib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2CLIMB [<xref rid="B36-pharmaceuticals-18-00262" ref-type="bibr">36</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tucatinib vs. Placebo added to trastuzumab and capecitabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">---</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.9 months vs. 14.7 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.6 months (tucatinib) vs. 5.4 months (placebo plus trastuzumab and capecitabine)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ADC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T-DM1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EMILIA [<xref rid="B27-pharmaceuticals-18-00262" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T-DM1 vs. Lapatinib plus capecitabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">---</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.9 months vs. 25.1 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.6 months (T-DM1) vs. 6.4 months (lapatinib plus capecitabine)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">T-Dxd</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TUXEDO-1 [<xref rid="B37-pharmaceuticals-18-00262" ref-type="bibr">37</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">---</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">---</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">---</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 months</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DESTINY-Breast03 [<xref rid="B38-pharmaceuticals-18-00262" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T-Dxd vs. T-DM1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">---</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">---</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.1 months (T-Dxd) vs. 7.2 months (T-DM1)</td></tr></tbody></table></table-wrap></floats-group></article>